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Abstract 
 Neural Stem Cells (NSC) are multipotent stem cells, capable of proliferating and 
differentiating in vivo and in vitro into astrocytes, oligodendrocytes and neurons. For this 
reason they hold a great potential for the development of gene and regenerative therapies for 
the treatment of neurodegenerative diseases and brain cancer. However, transfection of 
NSCs has proven to be difficult through conventional methods, and the disadvantages 
associated with the use of viral vectors make non-viral vectors more suitable for the 
development of gene delivery assays to NSCs. Apart from the non-viral method, one of the 
most important factors in gene delivery is the type of used vector. One of the factors that 
mostly affect the vector efficiency is the presence of CpG motifs. These motifs are 
responsible for the triggering of innate and acquired immune responses contributing to 
episomal silencing of the transgene. In this study, gene delivery to NSCs was optimized for 
the use of microporation technology and transfection efficiency was compared for the use of 
different transfection vectors with low vs. high CpG content, namely, minicircles, pCMV-GFP 
and pVAX-eGFP.     
 The optimization of microporation conditions revealed that depending on the 
electroporation buffer, high number of transfected cells (60 to 75%) and low cell mortality 
(15-10%) are obtained when using 1500V, 20 ms and 1 pulse or 1800V, 20 ms and 1 pulse 
as microporation conditions. When comparing the transfection efficiency using different 
vectors it was evident that Minicircle was the vector that allowed the obtainment of sustained 
and higher number of transfected cells (75%) without affecting their survival (80-90% of cell 
viability) and morphology. The quantification of vector copies in the nuclei revealed that the 
optimal dose to transfect NSCs is around 0.8 µg, and that, although a similar number of 
Minicircle and pCMV-GFP copies per nucleus is found, the first are the vectors that yield the 
highest expression levels. Long term analysis also showed Minicircles are less degraded, 
exhibiting higher number of copies and GFP expression than pCMV-GFP or pVAX-eGFP. 
Finally, microporation did not seem to affect NSCs differentiation potential.  
 Taken together, these results offer the first insights in the use of microporation and 
minicircles in non-viral transfection of NSCs, suggesting that microporation is a promising 
tool for NSCs transfection and that minicircles offer a new model of efficient and safe non-
viral gene delivery to NSCs and have unquestionably a potential use for clinical applications 
and genetic engineering. 
Keywords: CpG motifs; Microporatio; Minicircles; Neural stem cells; Non-viral gene delivery; 
plasmid DNA; 
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Resumo 
 Células estaminais representam um grupo específico de células indiferenciadas que 
apresentam a capacidade de se auto-renovar e de se diferenciar, quando estimuladas por 
determinadas condições, em células várias linhagens distintas. Existem dois tipos distintos 
de células estaminais: embrionárias e adultas. As células embrionárias apresentam a 
capacidade de se especificarem em vários tipos celulares no entanto, os problemas éticos 
muitas vezes associados com o seu isolamento e potencial cancerígeno, limitam o seu uso. 
Por este motivo, o interesse em células estaminais adultas, que apresentam apenas a 
capacidade de se especificar em tipos celulares provenientes do seu tecido de origem, tem 
vindo a aumentar exponencialmente.  
 Células estaminais neurais (Neural stem cells – NSC) representam uma população de 
células que pode ser isolada a partir de tecido cerebral embrionário, fetal ou adulto. No 
cérebro em desenvolvimento estas células existem como progenitores neuroepiteliais que se 
diferenciam em vários progenitores neurais que vão dar origem aos três tipos celulares 
característicos do sistema nervoso, astrócitos, oligodendrócitos e neurónios. No sistema 
nervoso adulto, estas células representam uma população de astrócitos que têm a 
capacidade de se diferenciar em caso de infecção ou inflamação, e habitam nichos 
específicos na zona subventricular do prosencéfalo e na zona subgranular do hipocampo. A 
sua capacidade única de se diferenciarem em células do sistema nervoso e de, após 
enxerto, conseguirem ultrapassar a barreira hematoencefálica, faz com que estas células 
apresentem um elevado potencial para o desenvolvimento de terapias regenerativas e 
genéticas para o tratamento de doenças neurodegenerativas e de cancro do cérebro.  
 Em cultura, estas células são aderentes ou formam complexos esféricos de 
progenitores neurais, apresentam a forma bipolar e expressam factores característicos de 
células neuronais, tais como nestina, Sox2 e Pax6, e astrogliais, tais como GFAP, GLAST, 
BLBP e RC2. A capacidade de diferenciação que estas células apresentam e o 
desenvolvimento de protocolos de diferenciação simples e eficazes fez com que as NSCs 
tenham sido alvo de diversos estudos de regeneração de tecidos e transferência de genes. 
Estudos recentes demonstraram que em caso de enxerto, as NSCs conseguem diferenciar-
se em neurónios dopaminérgicos e substituir lesões em modelos de doença de Parkinson e 
conseguem reduzir o processo inflamatório em modelos de esclerose múltipla. Em termos 
de entrega de genes, os estudos efectuados demonstraram que as NSCs podem ser 
transfectadas e entregar genes terapêuticos que potenciam o melhoramento de várias 
doenças de foro neurológico. 
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 Um dos grandes problemas até agora tem sido o desenvolvimento de métodos de 
transfecção eficientes. Até muito recentemente, a transfecção de NSCs era basicamente 
feita através de métodos virais, no entanto os problemas patogénicos associados a estes 
vectores e a possibilidade de indução de mutagénese das células transfectadas fez com que 
a atenção dos cientistas divergisse para as metodologias não virais. Em comparação com 
as primeiras, estas metodologias oferecem uma série de vantagens, tais como, maior 
capacidade de empacotamento, menor imunogenicidade, fácil e maior segurança de 
manuseamento. A entrega de genes usando estes métodos pode ser feita através de 
tratamentos químicos, como partículas de fosfato de cálcio, biopolímeros biodegradáveis e 
liposomas catiónicos, e através de tratamentos físicos, tais como sonoporação, 
bombardeamento de partículas, magnetofecção, electroporação e microporação. Para além 
do método de transfecção, há que ter em atenção o tipo de vector usado. Após transfecção, 
os vectores têm que ultrapassar barreiras extra e intracelulares que causam silenciamento 
episomal do transgene. É por este motivo que têm sido desenvolvidos muitos trabalhos com 
o intuito de melhorar os vectores. Um dos factores que mais afecta a eficiência de um 
plasmídeo é o conteúdo deste em motivos CpG. Estes dinucleótidos não-metilados são 
característicos de genomas bacterianos e, se presentes em plasmídos, são reconhecidos 
pelo sistema imunitário de mamíferos, mais especificamente por células que expressam 
TLR9, despoletando reacções imunológicas inatas e secundárias que levam à degradação 
do vector e posterior silenciamento do transgene. Recentemente têm sido produzidos 
plasmídeos de conteúdo reduzido em motivos CpG que em relação aos pDNAs 
convencionais, apresentam eficiência e persistência melhoradas. Para além destes tipos de 
vectores, o desenvolvimento da tecnologia de minicirculos, que são pequenos vectores 
desprovidos de sequências bacterianas e de conteúdo CpG reduzido, permitiu um 
melhoramento de 10 a 10,000x das eficiências de transfecção em relação aos pDNAs 
convencionais. O objectivo principal deste estudo foi a optimização das condições de 
transfecção não viral de NSCs (CGR8-NSC) por microporação e a comparação das 
eficiencias de transfecção de NSCs quando transfectadas com minicirculos e pDNAs com 
conteúdo em motivos CpG reduzido ou mesmo inexistente.  
 Neste estudo, foram feitas duas optimizações das condições de microporação para o 
uso de dois tampões de electroporação diferentes, o RB, um tampão de formulação 
desconhecida, e o HMB, um tampão preparado no laboratório e que já tinha sido utilizado 
para transfectar células HEK293T e células estaminais mesenquimatosas. A microporação 
com o tampão RB foi feita transfectando pVAX-eGFP e variando a voltagem (entre 1400 e 
1600V), a duração do pulso (20 e 30 ms) e o número de pulsos (1 e 2). A condição que no 
geral demonstrou ser mais eficaz foi 1500V, 20 ms e 1 pulso (percentagem de células 
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transfectadas ≈ 60%; viabilidade e recuperação celular 85-90%). A optimização com HMB foi 
feita microporando as NSCs com dois vectores diferentes (pVAX-eGFP e MC-GFP) e 
variando a voltagem entre 1600 e 1900V. Apesar de, com o aumento da voltagem se ter 
verificado, em ambos os casos, uma diminuição das viabilidades e recuperações celulares 
(mais acentuada em células transfectadas com pVAX-eGFP), no geral, a condição que 
obteve os melhores resultados, exibindo as percentagens de células transfectadas (50 e 
75% com pVAX-eGFP e PC-GFP) e rendimentos de transfecção (47 e 69% com pVAX-
eGFP e MC-GFP) mais elevadas foi 1800V, 20 ms e 1 pulso. Um outro ensaio de 
optimização foi efectuado para determinar a quantidade ideal de DNA para transfectar 
NSCs. Para isto, NSCs foram ressuspendidas em RB e transfectadas com várias 
quantidades de pVAx-eGFP (0.5, 0.8, 1.0 e 1.5 µg) usando 1500V, 20 ms e 1 pulso como 
condições de microporação. Apesar de o aumento de DNA não ter afectado a percentagem 
de células GFP+ (≈50%) e de ter provocado uma diminuição das viabilidades e recuperações 
celulares, 0.8 µg foi a quantidade de pDNA que exibiu o maior rendimento de transfecção 
(≈40%), tendo sido por isso considerada a quantidade ideal de vector para transfectar NSCs.  
 Para testar a eficiência de transfecção de minicirculos e outros pDNAs com conteúdo 
reduzido ou inexistente em CpGs as NSCs foram transfectadas com 2.0 x 1011 moléculas de 
cada vector. A transfecção com plasmídeos sem motivos CpG (pCpGfree-eGFP) revelou-se 
muito aquém do esperado, e quando comparando com NSCs transfectadas com pVAX-
eGFP, a percentagem de células GFP+ era menor e o decaimento da expressão do 
transgene ao longo do tempo mais rápido em células transfectadas com pCpG-eGFP, 
indicando que talvez, o promotor deste plasmídeo não seja tão eficiente como o do pVAX-
eGFP. Comparando células transfectadas com minicirculos (MC-GFP) com outros pDNAs 
(pCMV-GFP – plasmídeo correspondente de MC-GFP, e pVAX-eGFP) verificou-se que 
usando MC-GFP é possível manter elevados níveis de células transfectadas (≈75%) sem 
comprometer a viabilidade celular (80-90%) e a morfologia bipolar característica das NSCs 
em cultura. Adicionalmente, a expressão do gene mantém-se mais alta com MC-GFP ao 
longo de 10 dias e não afecta a proliferação celular.  
 Testes adicionais foram efectuados para quantificar o número de cópias de vector no 
núcleo de NSCs transfectadas. Em estudos anteriores tinha-se verificado que há uma certa 
dose de plasmídeo a partir do qual a expressão do transgene satura. Em NSCs verificou-se 
que, independente do vector, a partir de 0.8 µg há uma estabilização e posterior decaimento 
da expressão da GFP, e, quando comparando o número de cópias de cada vector no 
núcleo, verificou-se que apesar da quantidade de MC-GFP e pCMV-GFP ser semelhante, o 
nível de expressão do primeiro era mais elevado. Adicionalmente, a análise ao longo de 10 
dias da quantidade de cópias do núcleo revelou que o MC-GFP era o vector que se 
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encontrava em maior quantidade no núcleo e o que revelava maiores níveis de expressão 
do transgene, indicando que este, devido ao seu menor tamanho e conteúdo CpG mais 
reduzido (≈6%) é menos degradado que os outros plasmídeos. Em comparação, os 
resultados com pCMV-GFP e pVAX-eGFP, que apresentam conteúdo semelhante em 
motivos CpG (≈7%), diferem muito entre si, apresentando o pCMV-GFP eficiências e 
viabilidades celulares mais elevadas. Este facto é difícil de ser explicado mas há três 
diferenças entre estes dois plasmideos que podem justificar esses valores: i) diferente sinal 
de poliadenilação dos dois plasmídeos (pVAX-eGFP apresenta o sinal BGH e o pCMV-GFP 
apresenta o sinal SV40), que como estudos anteriores já demonstraram pode influenciar os 
níveis de expressão, ii) diferenças na sequência do gene reporter que pode originar uma 
proteína com maior ou menor intensidade de fluorescência; iii) ou ao nível de purificação de 
cada plasmídeo. Finalmente, nem o uso de microporação nem a transfecção com plasmídeo 
afectou a capacidade de diferenciação das NSCs em neurónios.  
 Comparando os resultados obtidos é possível concluir que o uso de microporação como 
método de transfecção de NSCs dá origem a elevadas eficiências de transfecção. Em 
comparação com os outros pDNAs, os Minicirculos foram os vectores que demonstraram as 
melhores eficiências de transfecção e os maiores níveis de expressão do transgene sem 
comprometer a morfologia e a viabilidade das células. Pode-se concluir que o tamanho 
destes vectores e que a diferença e 1% no conteúdo em motivos CpG é suficiente para que 
o silenciamento episomal do transgene seja mais fraco com MC-GFP. Como trabalho futuro, 
seria interessante avaliar a expressão de TLR9 em NSCs após transfecção para verificar se 
há realmente silenciamento devido aos motivos CpG e quantificar o RNA mensageiro para 
avaliar a estabilidade e frequência do transgene. Seria também muito benéfico avaliar a 
eficiência dos minicirculos através de transfecção por outros métodos não virais, tais como, 
lipofecção ou magnetofecção, e efectuar estudos in vivo para avaliar o tráfico intracelular de 
minicirculos, e também clonar um gene de interesse nos minicirculos para avaliar o seu 
potencial no desenvolvimento de futuras terapias para doenças de foro neurológico.    
 Até à data, ainda não tinham sido efectuados estudos de transfecção em NSCs usando 
microporação ou minicirculos. Este trabalho representa a primeira perspectiva para o uso 
destas tecnologias para a transfecção destas células e indica que os minicirculos 
representam um novo modelo eficiente e seguro de entrega não viral de genes para NSCs e 
uma alternativa muito promissora para o desenvolvimento de terapias para o tratamento de 
doenças neurodegenerativas ou cancro do cérebro onde uma expressão transiente de 
transgene pode ser necessária. 
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1. Introduction 
1.1. Stem cells  
A stem cell is a specific type of cell that has the potential to differentiate into one or more 
specialized cell type and the unique capacity of self-renewal for an expanded period of time. 
Unlike the majority of cells which are committed to conduct a specific function, a stem cell 
maintains an unspecialized state until it receives  signals to differentiate into a tissue- or 
organ-specific cell kind [2]. Due to their special proliferative capacity and high plasticity, 
these cells represent an invaluable tool to basic research and an incredible resource for the 
repair and regeneration of diseased or damaged  cells and tissue [3]. 
Stem cells can be found since the early stage of the embryo until the end of life and can 
be categorized as embryonic or adult, depending on their tissue of origin. Embryonic stem 
cells are derived from the inner cell mass of the blastocyst (4 to 5- day embryo) and possess 
the remarkable property of pluripotency, giving rise to a wide variety of cell types 
representative of the three primary germ layers in the embryo (mesoderm, endoderm and 
ectoderm) [3-4]. For this reason, they hold a great promise for tissue engineering and cell 
replacement therapies, however, their potential use in biomedical treatments is still 
controversial due to ethical concerns related to their isolation and because of their 
tumorigenic potential [5]. 
 Adult stem cells are lineage-restricted undifferentiated cells, i.e. multipotent cells, with 
the capacity of giving rise to progeny cells of their correspondent tissue of origin [6]. These 
tissue-specific cells are scarce and present in a metabolically quiescent state in specialized 
tissues, such as the brain, bone marrow, liver, skin and gastrointestinal tract. Nowadays, on 
account of their high accessibility and minimally invasive harvesting procedures, there is a 
rising interest in these cells. The best known example of adult stem cell is the Hematopoietic 
stem cell (HSC) which can be isolated from the bone marrow niche and has the capacity to 
originate all blood cell types.  Mesenchymal stem cells (MSC) and Neural stem cells (NSC) 
are other good examples of well studied adult multipotent cells. MSC have the potential to 
differentiate into different mesodermal cell lineages and are present in almost all tissues, 
however for therapeutic applications they are preferably isolated from the bone marrow and 
the umbilical cord blood [7]. NSC can be isolated from embryonic, fetal or adult brain tissue 
and are capable of generating neurons and glia in the developing brain. In the mammalian 
adult brain NSCs exist in niches that support symmetric self-renewal and fate-committed 
asymmetrical divisions that potentiate de replacement and recovery of lost neural cells [8].  
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1.2. Sources of Neural Stem Cells 
1.2.1. Embryonic neurogenesis  
The main features of Neural Stem cells (NSCs) reside in their ability to self-renewal, 
proliferate and generate multiple cellular lineages, such as neurons, astrocytes and 
oligodendrocytes both in vivo and in vitro. Their morphological and phenotypic identities vary 
depending on the developmental stage and region occupied by these cells during adult life. 
In the early embryonic stage, predetermined programs give rise to spatiotemporally different 
NSC populations in a process called Neurogenesis. This process begins with the induction of 
the neuroectoderm, which forms the neural plate that folds to originate the neural tube. In the 
embryonic neural tube, NSCs exist as neuroepithelial stem cells that undergo differentiation 
into distinct neural progenitors and posterior specification into neuronal lineages through 
asymmetrical cell divisions in the germinal ventricular zone (VZ). After the neurogenic phase 
NSCs acquire gliogenic competence and start differentiating into glia in the subventrivular 
zone (SVZ). This process leads to the specification of astrocytes and the disappearance of 
the VZ. After brain development, some parts of the brain still harbor sites where adult 
neurogenesis remains active with the sole purpose of maintaining homeostasis of the central 
nervous system (CNS) [9].  
1.2.2. Neural differentiation of embryonic stem cells 
The understanding of the processes involved in embryonic neurogenesis and the 
progress in cell culture methodologies enabled the development of protocols that induce 
neuralization of ESCs in vitro.  The overall advantage of ESC derived NSCs is that these 
cells retain a developmental competence to patterning signals giving rise to regional 
subtypes that can be transplanted in vivo and differentiate into functional neuronal entities. 
Early ESC neuralization attempts reported that, in minimal inductive conditions [10], ESCs 
were capable of differentiating into progressive neural progenitors that expressed distinct 
neural markers [11], however, the resulting cultures had a heterogeneous profile 
characterized by the coexistence of undifferentiated ESCs and different neural progenitors. 
Therefore, new protocols, based on the production of embryoid bodies [12], or stromal feeder 
co-cultures [13] were developed. Under these conditions, the originated cell populations 
exhibited uniform biochemical and electrophysiological characteristics.  Nowadays, with the 
increasing comprehension of the developmental and functional mechanisms of ESC derived 
neurons, more effective procedures are being established. Recently, Chambers and 
colleagues, based on the understanding of the involvement of the SMAD signaling pathway 
in neural induction, developed a new protocol in which a dual-SMAD inhibition, by the 
synergistic action of Noggin and SB431542, induced rapid and complete neural conversion 
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of human ESCs [14]. Apart from ESCs, induced pluripotent stem cells (iPS) represent 
another great source of cells for differentiation into NSCs. Many protocols for neuralization of 
iPS are being developed and they provide a unique opportunity for the development of 
autologous therapies and tissue replacement [15].       
1.2.3. Adult neural stem cells 
Adult Neural Stem Cells (aNSCs) are present in specific niches in the subventricular 
zone (SVZ) and subgranular zone (SGZ) of the adult brain where they undergo adult 
neurogenesis. In these areas, their regulation is managed by fate—controlling molecules and 
signaling pathways. These molecules are members of the fibroblast and epidermal growth 
factor families and permit the expansion and specialization of adult neural progenitors in vivo 
and in vitro. Some of the most studied mediators are:  epidermal growth factor (EGF) [16] 
and platelet-derived growth factor (PDGF-α) [17], that induce gliogenic specification, and 
fibroblast growth factor (FGF) [18], Sonic hedgehog (Shh) [19] and brain-derived 
neurotrophic factor (BDNF) [20] that are responsible for the differentiation into neuronal cells. 
In vivo, neurogenesis is regulated by the action of immune effector cells called microglia that 
are abundantly present in the adult CNS. During an injury, microglia secretes neurotrophic 
and neurogenic factors that potentiate the recovery of the damaged regions and increase the 
neurogenic process [21-22].  
The most active zone of adult neurogenesis is the SVZ of the forebrain. This area 
contains a subpopulation of astrocytes that function as aNSCs in vivo and are known as 
Type-B cells, which in turn, can be subdivided in Type B1 and B2 cells. Type-B1 cells are 
considered true aNSC and are in contact with the ventricular cavity where, in response to 
vascular signals, differentiate into neural progenitors (Type C cells). These progenitors 
undertake symmetrical divisions and give rise to neuroblasts (Type A cells) that migrate 
through the rostral migratory stream, aided by Type B1 and B2 cells, to the olfactory bulb 
where they specify as interneurons. In the SGZ in the dentate gyrus of the hippocampus, 
neuronal progenitors (Type-B cells) differentiate into granular neurons. However, these 
neuronal progenitors have a limited capacity of specification. They suffer asymmetrical 
divisions that instigate a regionally determined differentiation into granular neurons that act 
as regenerative entities in the brain [23].   
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1.3. Characterization of NSCs  
1.3.1. In vitro proliferation of NSCs 
NSCs can be proliferated as Neurospheres or in adherent conditions. After isolation 
NSCs are plated in low attachment tissue culture plastic dishes in serum-free media 
supplemented with the mitogens EGF and FGF [24].   Under these conditions cells that are 
undergoing specification die and NSCs form free-floating aggregates. The Neurosphere 
system is thought to provide a three dimensional environment that mimics neurogenic niches 
[25], however long-term cultures of neural progenitors as aggregates are difficult to maintain 
due to the occurrence of changes in the differentiation and self-renewal capacities, and the 
incidence of chromosomal instability [26-27]. 
 In the first approaches, the adherent system involved, , expansion of NSCs on 
biopolymer-coated dishes in serum-free conditions [28]. These procedures permitted the 
exploration of NSCs multipotentiality but the cultures were short-termed and did not allow an 
efficient immortalization. Nowadays adherent propagation of NSCs is performed under the 
action of EFG and FGF-2 [29], or, as recent data show, under exposure to angiogenic factors 
[30].  In these conditions, cells undertake symmetrical divisions, maintain an undifferentiated 
state for a long period of time and retain their tripotential differentiation capacity.  
1.3.2. In vitro differentiation of NSCs 
Due to the potential that NSCs have to differentiate into neurons, astrocytes and 
oligodendrocytes, a number of protocols have been developed for controlled in vitro 
specification in one of the three possible fates. Differentiation within neurospheres is 
achieved by mitogen removal after attachment onto substrate coated coverslips [29]. Under 
these conditions NSCs form primary neurospheres and specify into neuronal progenitors. 
Upon replating the neural progenitors give rise to secondary aggregates where they 
differentiate into GABAergic interneurons, astrocytes and oligodendrocytes, however, with 
the posterior passages, the maintenance of neurogenic competence declines and the yield of 
gliogenesis increases thus originating an uncontrolled pattern of differentiation. In the 
monolayer adherent system, NSCs give rise to antigenically and electrophysiologically 
mature neurons, oligodencrocytes and astrocytes after prolonged expansion under optimized 
differentiating conditions [29, 31-32]. These in vitro differentiated cells can be efficiently 
transplanted into the brain and establish synaptic connection with the cells of the nervous 
system [33].  
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1.3.3. In vivo and In vitro phenotype of NSCs 
There are currently four types of known phenotypically distinct NSCs: Neuroepithelial 
progenitors (NEP), Radial Glia (RG), Basal Progenitors (BPs) and Adult neural stem cells 
(aNSCs).  
NEPs are present during the embryonic development of the CNS and express nestin, 
Sox1, Sox2 and Pax6, markers for immature neural cells, and some ESC markers, such as 
Oct4. The expression of nestin, Sox2 and Pax6 persists throughout the specification of 
primitive NEPs into the subsequent neural progenitors and is essential to the neurogenic 
process [34-36]. In vitro, these primitive NSCs lose the expression of ESC markers with the 
passages and become more committed to specify into neural progenitors. At the beginning of 
neurogenesis, NEPs give rise to RGs that serve as the main progenitors in the developing 
brain. RGs express astroglial markers, such as astrocyte specific glutamate aspartate 
transporter (GLAST), glial fibrillary acidic protein (GFAP), brain-lipid binding protein (BLBP) 
and RC2, and neurogenic markers like nestin, Sox2 and Pax6. Recent findings suggest that 
RGs can also be found in a non-ventricular niche in the adult spinal cord of mice (SCRGs) 
and are phenotypically similar to adult NSCs of the SVZ [37].  
In the adult brain, BPs potentiate the production of neurons, however, their propagation 
in vitro is difficult so little is still known about them. Adult NSCs are the main progenitors of 
adult neurogenesis and combine the expression of radial glial markers, like GFAP, GLAST, 
BLBP and RC2; neural precursor markers like, nestin, Sox2 and Pax6; regional markers like 
Otx2 and Hoxb9 and others like Musashi 1 and CD133 that maintain their stemness. In vitro, 
aNSCs are antigenically similar to neurogenic RGs in the brain when grown in adherent 
conditions; however, when propagated as neurospheres, their phenotype is characterized by 
the presence of differentiated cells in the sphere core surrounded by RG-like neural 
progenitors [8, 26, 32].  
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1.4. Therapeutical applications of NSCs 
 In recent years, the successful production of neurons and glia from stem cells in culture 
fuelled efforts to develop stem-cell-based transplantation therapies for neurological 
disorders. It is well known that within the CNS, endogenous neural progenitors support its 
‘self-repair’ during inflammatory disorders, such as spinal cord injury and stroke [38-39]. 
Although efficient, endogenous stem cells are not able to promote full and irreversible repair 
of the CNS. Adult neurogenesis is highly influenced by the surrounding microenvironment, 
and, upon inflammation, the supporting cells secrete molecules that attract inflammatory 
cells. NSCs can perceive these changes as dysfunctions and induce an uncontrolled 
neurogenic process [40]. 
 Nowadays, many laboratories are diverting their attention to the development of 
therapies for many CNS disorders, such as, Parkinson’s disease, Huntington’s disease, 
multiple sclerosis, stroke, traumatic brain injury, Alzheimer’s disease, epilepsy, and others. 
These diseases are characterized by progressive neuronal degeneration that can ultimately 
be fatal.  Stem-cell based approaches for these diseases involve the engraftment of in vitro 
propagated NSCs or differentiated neuronal cells for the restoration of a lost function. When 
transplanted they have low immunogenicity, are able to migrate and overcome the blood-
brain barrier, and upon transfection, allow vector-directed differentiation or drug delivery [41].  
Many studies have documented that neural progenitors, for instance, can be efficiently 
engrafted to Parkinson’s disease models, migrate to the injured areas and specify into 
dopamine neurons [42], can survive, migrate and differentiate under the influence of the 
surrounding microenvironment in stroke models [43] or can reduce brain inflammatory 
process in multiple sclerosis models [44]. 
 NSCs can also be used as drug delivery vehicles. They can be transfected and produce 
specific neurotrophic or neuroprotective factors that promote a long-lasting amelioration and 
regression of the symptoms of neuronal disorders. A few authors have published results 
regarding, for example, the delivery of GDNF engineered NSCs to PD and amyotrophic 
lateral sclerosis models [45-46], the delivery of NGF or BDNF to AD models [47-48], or the 
delivery of VEGF to promote recovery in SCI models [49-50].  NSC based gene therapy also 
represents a promising tool for the treatment of brain tumors by the delivery of molecular 
agents that promote the conversion of prodrugs into anticancer substances, and 
immunostimulating cytokines [51].  
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1.5. Gene delivery to NSCs 
1.5.1. Viral methods 
 Lately, many efforts have been made to improve the transfection efficiency of NSCs in 
order to provide better opportunities for future therapeutic applications. Viruses like retrovirus 
and lentivirus integrate into the host genome and allow stable gene transfer and long-lasting 
expression. In contrast, adenovirus and adeno-associated virus (AAV) are non-integrating 
particles that cause no side effects in humans, and allow transient expression of the 
transgene [52].  Although efficient, there are still some drawbacks related to their use. These 
vectors have limited transgene capacity, trigger cytotoxic and immunogenic reactions, cause 
mutagenesis due to their random integration in the host genome [52-53], and in NSCs they 
affect differentiation and block neurogenesis [54]. At present, a special attention is being 
given to AAV vectors. These vectors were initially considered nonintegrative and 
nonpathological however, it has been demonstrated that they integrate into the host genome 
and trigger malignant transformation of the cells [55-56]. Nevertheless,   some of the newest 
methodologies for gene delivery take advantage of their demonstrated capacity and available 
capsid libraries to design new hybrid vectors that consist of AAV packaged plasmids [57]. 
1.5.2. Non-Viral methods 
 Regardless of having lower transfection efficiencies and low cell viabilities, there’s an 
increasing interest in non-viral gene delivery methods. When compared to viral methods, 
non-viral methods are cheaper, easier to manage, have a wider range of putative cell targets, 
lower immunogenicity, lesser toxicity, bigger packaging capacity and allow transient 
expression, a feature that might be beneficial for therapeutic strategies where a short 
duration of transgene expression is necessary [58]. These methods are used to transfect 
different molecules, such as, RNAs (e.g. siRNAs), proteins (e.g. antibodies) and DNA which 
is mostly delivered as plasmid vectors (pDNA) that have been cloned to contain a transgene 
expression cassette [59], and rely on a physical treatment or on chemical or biological 
particles that are used as carriers.   
 Some of the most used chemical DNA delivery methods are:  
 Calcium phosphate-mediated transfection which involves incubation of the cells with 
calcium phosphate coated pDNA. This method is very efficient yet restricted to some 
cells and sensitive to the amount of input pDNA [60]. 
 Biodegradable cationic polymers that are used for the controlled release of DNA into the 
cell or tissue of interest. These polymers have a reduced toxicity and avoid polymer 
accumulation in the cells, however, their slow degradation rate and the inefficient 
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membrane destabilizing peptides available influence the effectiveness of these 
structures [61]  
 Cationic liposomes which are vesicular structures of positively charged lipids that once 
surrounding DNA form lipoplexes. These systems have a low toxicity in vitro, but can 
exhibit some toxicity and low transfection efficiencies in vivo due to the physiochemical 
properties of the cationic lipid/DNA complexes [62].  
 The most popular physical DNA delivery systems are:   
 Sonoporation that consists on the permeabilization of the cell membrane through 
exposure to low-field ultrasounds that induce the uptake of large molecules into the cell. 
This technique is used in targeted gene transfer both in vivo and in vitro, however, 
extended exposure to low-field ultrasounds results in increased cell mortality, thus the 
procedure needs to be carefully applied [62]; Gene gun which is based on the 
precipitation of DNA on small particles of a heavy metal, usually gold, and posterior 
injection, using a pistol. At present there are many listed gene gun clinical trials for 
Hepatitis B, malaria and influenza yet, this method is only applicable on superficial 
tissues (e.g. skin) due to the high level of cell damage caused by the velocity of the 
particles [62]; 
 Magnetofection that involves the association of the DNA with magnetic nanoparticles 
which are transferred to the cells by the application of a magnetic field.  Although 
promising, the use of magnetofection in vivo is still limited due to the inaccessibility of 
the targeted tissues to magnetic field and hydrodynamic forces. Ongoing improvements 
of this procedure involve, in some cases, the combination of the magnetic complexes 
with cationic lipids [62-63]; 
 Electroporation, which is a powerful tool that relies on the application of a short electric 
pulse that leads to a permeable state of the cell membrane so that the molecules can be 
driven into the cell through elecrophoretic and electro-osmotic forces. This technique is 
used to transfer molecules of different sizes (e.g. genes, proteins, ionic dyes and drugs) 
into the cell, however, there are still some problems needing to be solved such as low 
viabilities and transfections caused the massive cell mortality triggered by the electric 
pulse [62]; To overcome some of the problems associated with electroporation, a new 
technology called Microporation was developed. This new layout provides high 
transfection efficiencies and cell viabilities and is based on the use of a pipette tip as 
electroporation area and a capillary electrode which allows maintenance of pH and 
temperature, minimizes turbulence and avoids ion metal generation [64].  Recent studies 
have proven that microporation is an easy and efficient method for gene delivery to a 
wide variety of cells, such as, Human bone marrow mesenchymal stem cells [65], 
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Human astrocytoma cells [66] and Human umbilical cord blood-derived mesenchymal 
stem cells (hUCB-MSCs) [67].  
 Even though these non-viral methods have shown to be effective and advantageous, it is 
important to optimize these technologies to allow better in vivo and in vitro transfection 
efficiency and permit the development of new therapeutic strategies. These improvements 
involve not only the development of new gene transfer technologies, but also the 
enhancement of transfection vectors that need to overcome many extra- and intracellular 
barriers.    
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1.6. Minicircles: The future of gene therapy? 
Upon administration there are a number of extra- and intracellular systems that can 
impair gene delivery. Extracellularly, the vectors can be sequestrated in first pass organs 
(e.g. lung and liver) or affected by the extracellular matrix [68]. Intracellularly, the vectors 
encounter two distinct cytosolic barriers: a diffusional and a metabolic barrier. The diffusional 
barrier is related to the size-dependent deceleration of the vectors which might lead to the 
emergence of plasmid aggregates and an increase of the cytoplasm viscosity. The metabolic 
barrier is related to the presence of calcium-sensitive cytosolic nucleases that degrade 
foreign DNA [68-69]. The nuclear envelope represents the last barrier to be surpassed and to 
diffuse through the nuclear envelope the vectors must carry a nuclear localization sequence 
(NLS) to pass through the nuclear pore complex (NPC) or be transfected in dividing cells to 
gain access to the expression machinery after nuclear disassembly during mitosis [70].  
To overcome these barriers many laboratories have been committed to the development 
of more effective plasmid vectors. Conventionally, pDNA is constituted by a mammalian 
expression cassette and a bacterial backbone consisting of an antibiotic resistance gene and 
an origin of replication for production in bacteria. To avoid degradation pDNA should be 
stable and mainly in the supercoiled form and free of contaminating factors (e.g. bacterial 
DNA, RNA and proteins). Many of the most recent advances in plasmid technology involve 
the substitution of the conventional polyadenylation (polyA) signals with more effective polyA 
sequences (e.g. Bovine growth hormone (BGH) polyA and SV40 polyA), that extend the half-
life of supercoiled pDNA thus preventing the transformation into a circular form and exposure 
of secondary structures to the host nucleases [71], and the development of CpGfree 
plasmids. Unmethylated CpG motifs are predominantly present in bacterial DNA and 
therefore, are also common in bacterial derived pDNAs. These motifs are recognized by Toll-
Like receptor 9 (TLR) positive cells (e.g. Dendritic cells) which activate host defense 
mechanisms triggering innate and acquired immune responses [72]. Transfection of CpGfree 
based pDNA has proven to yield high transgene expression in vivo and in vitro hence 
allowing sustained expression [73].  
The real breakthrough in the vector upgrading was the development of the minicircle 
technology. Minicircle DNAs are small sized circular molecules, derived from plasmid DNA, 
that lack the bacterial backbone that triggers immune responses, alters gene expression and 
might potentiate the silencing of the encoded transgene. This technology consists on the 
construction of a parental plasmid that carries the expression cassette flanked by two 
recognition sites of a site-specific recombinase (e.g. λ derived recombinase; Cre rec.; FLP 
rec.) which is expressed and divides the parental plasmid into two molecules: a miniplasmid 
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that carries the bacterial backbone and a minicircle that carries the expression unit. One of 
the major drawbacks of minicircle technology was, until recently, the difficult and expensive 
purification procedure of these vectors [62]. To overcome these hardships, Chen and 
coworkers developed a new method that degrades the remaining miniplasmid and parental 
plasmids in vivo by the action of a restriction enzyme (SceI), hence allowing a more effective 
purification [74], and more recently, the development of a robust minicircle production system 
permitted the establishment of a rapid and inexpensive protocol for production of minicircles 
[75]. When compared to regular plasmids, minicircles display a 10- to 10,000-fold 
improvement in long-term transgene expression in vivo [76-77], and, further improvements in 
their formulation, e.g. addition of scaffold/matrix attachment region (S/MAR), enhances 
transgene expression and persistence [78].  Altogether, this data confirm that minicircles 
offer a new concept in highly efficient and safe non-viral gene transfer, and in the future, they 
will represent the preferred system for gene delivery for clinical and therapeutic applications.  
In this work, microporation conditions were optimized for gene delivery to NSCs for the 
use of two electroporation buffers, RB, the buffer provided by the manufacturer, and HMB, a 
buffer previously prepared at the laboratory. Furthermore, transfection efficiency was tested 
and compared using minicircles and pDNAs of different sizes and CpG content. Stem cell 
potential was investigated by evaluating the survival, proliferation, and differentiation 
potential of transfected cells and the number of copies of vector DNA was assessed in each 
case, more specifically, after Minicircle, pCMV-GFP and pVAX-eGFP transfection and the 
optimal dose of vector DNA for gene delivery to NSCs was determined. These results 
strongly suggest that there is a CpG dependent episomal transgene silencing in transfected 
NSCs and that minicircles are the vectors that give rise to the highest levels of gene 
expression without influencing the cell traits of NSCs.  
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2. Aim of Studies 
This study was fully accomplished at Stem Cell Bioengineering Laboratory in Institute for 
Biotechnology and Bioengineering at Instituto Superior Técnico.  
This work focused on the following points: 
 Optimization of microporation conditions for gene delivery to NSCs by evaluating the 
effect of voltage, pulse duration, electroporation buffer and DNA amount.  
 Evaluation of the GFP expression levels upon transfection of CGR8-NS cells with 
CpGfree plasmids. 
 Comparison of the use of different gene vectors with different CpG content, more 
specifically, minicircles, pCMV-GFP and pVAx-eGFP in NSCs transfection – evaluation 
of cell viability, percentage of GFP expressing cells, proliferation kinetics and 
morphological traits.  
 Quantification of the number of vector copies inside each nucleus after transfection with 
minicircle, pCMV-GFP and pVAX-eGFP, and determination of the ideal dose of vector 
after which transgene expression saturates. 
 Evaluation of dilution kinetics of each vector – quantification of the number of vector 
copies inside the nucleus after transfection with minicircles, pCMV-GFP and pVAX-
eGFP at specific points for 7-10 days. 
 Differentiation of CGR8-NSCs – effect of transfection on differentiation potential. 
The results obtained by this study will certainly be useful for future gene delivery 
applications in Neural Stem Cells, in particular, for the development of tissue regeneration 
applications and gene therapies for the treatment of neurodegenerative diseases or brain 
cancer where a transient expression of a gene of interest might be necessary.  
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3. Materials and Methods 
3.1. Plasmids and Minicircles 
3.1.1. Plasmids and Minicircles encoding GFP 
The transfection vectors MC07.CMV-GFP (2257 bp), that will be referred as MC-GFP, 
and pCMV-GFP plasmid (3487 bp), both carrying the same  GFP gene under the control of 
the cytomegalovirus (CMV) promoter and the SV40 polyadenylation sequence, were 
purchased from Plasmid factory (Bielfield, Germany). MC-GFP is a bacterial backbone vector 
consisting only on a mammalian expression cassette and pCMV-GFP is its correspondent 
plasmid which contains, apart from the expression cassette, an origin of replication and a 
Kanamycin resistant gene for prokaryotic selection. The pVAX-eGFP plasmid (3697 bp) was 
obtained by the modification of the commercial plasmid pVAX1lacZ (Invitrogen, 6050 bp) by 
replacement of the lacZ reporter gene with the enhanced Green Fluorescent protein gene 
(eGFP)(Supplementary Fig.1). The details of this construction are described elsewhere [1] 
and this plasmid was isolated and purified from a pVAX-eGFP transformed E. coli strain 
stored at -80 ºC.   
3.1.2. Construction of CpGfree plasmids encoding GFP 
a) CpGfree plasmid 
The CpGfree plasmid (3049 bp, Invivogen) is a commercial vector consisting of 
elements devoid of CpG dinucleotides and Dam methylation sites (GATC). This plasmid 
contains: a R6Kγ origin of replication, a E2MK promoter, a ZeocinTM resistance gene, and in 
the eukaryotic expression vector the promoter combines the mouse CMV enhancer, the 
human elongation factor 1 alpha core promoter and 5’UTR containing a synthetic intron, the 
late SV40 polyadenilation signal, matrix attachment regions (MARs) and a multiple cloning 
site (MCS). 
b) Reconstitution of E. coli GT115 strain 
The reconstitution of E. coli GT115 (provided with pCpGfree) was performed by 
adding 1 ml of LB medium to the tube containing the strain and incubation for 5 minutes at 
room temperature. The cell suspension was then mixed for 2 minutes and 100 µl of this 
suspension was plated in LB-Agar and incubated overnight at 37ºC. The resulting colonies 
were used to prepare competent cells (see below section 3.1.4).  
c) Cloning of eGFP into CpGfree plasmids 
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The eGFP gene was amplified from the pVAX-eGFP vector. Briefly, 100 µl of E. coli 
transformed with pVAX-eGFP plasmids was inoculated in 5 ml falcons supplemented with 50 
µg/ml Kanamycin and grown overnight at 37ºC and 250 rpm. The plasmid was then purified 
according to the protocol described in section 3.1.6 and its integrity verified through 
enzymatic digestion with HindIII and Agarose gel electrophoresis analysis. The eGFP gene 
was amplified by Polimerase Chain Reaction (PCR), using the following primers:  NcoI-GFP-
Fwd, 5’- AAACCATGGATGGTGAGCAAGGGCGA -3’; and GFP-NheI-Rev, 5’- 
TTTGCTAGCTTACTTGTACAGCTCGTCCATGCC -3’ (STAB Vida). Each 50 µl of final 
reaction volume contained 10 ng of pVAX-eGFP, 10 µM of each primer, 25 µl of KOD Hot 
Start Master Mix (Novagen 
®
), and 20 µl of Distilled H2O. The reaction was subjected to the 
following conditions: 5 min at 95ºC, 35 cycles of 30 s at 95ºC, 60 s at 60ºC and 90 s at 72ºC 
and 5 min at 72ºC. The amplification of the eGFP fragment was assessed through Agarose 
gel electrophoresis analysis and its purification was made using a DNA extraction and 
purification from Agarose gel kit (NZYTECH).  The CpGfree-eGFP plasmid was then 
constructed through enzymatic restriction with NcoI and NheI and subsequent insertion of the 
eGFP reporter gene using T4 DNA Ligase. The construction was later confirmed through 
double enzymatic digestion with NcoI and NheI and Agarose gel electrophoresis analysis. 
The production and purification of this plasmid is described in section 3.1.8.  
3.1.3. Production of Minicircles 
a) Propagation of the Parental plasmid 
The Minicircle DNA vector technology was purchased from System Biosciences (SBI; 
Mountain View, California) and the propagation of the Parental plasmid (PP-DNA, ≈7.8 Kb) 
was performed in an E. coli XLlgold strain and in an engineered E. coli ZYCY10P3S2T strain 
(provided by the manufacturer) as described below (Section 3.1.5). 
 
b) Transformation of the Parental plasmid into E. coli ZYCY10P3S2T 
The Transformation of the PP-DNA into E. coli ZYCY10P3S2T was performed as 
described by the manufacturer. Succinctly, 2 µg of MC-DNA was added to 100 µl of cells, 
incubated on ice for 30 minutes and at 42ºC for 30 seconds. The cell suspension was then 
placed on ice for 2 minutes after which 500 µl of S.O.C. medium supplemented with 
Kanamycin (50 µg/ml) was added. The mixture was then incubated for 60 minutes at 37ºC 
and 225 rpm. Afterwards, the cells were centrifuged for 10 minutes at 4000g, resuspended in 
100 µl of S.O.C medium, plated on LB-Agar with 50 µg/ml of Kanamycin and incubated 
overnight at 37ºC. Some colonies were then harvested and cultured overnight, at 37ºC and 
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250 rpm, in 5 ml LB falcons with antibiotics. The presence of the PP-DNA was assessed 
through agarose gel electrophoresis analysis after simple enzymatic digestion with HindIII. 
c) Induction assays for minicircle production 
 On day 1 in the morning, cells from a PP-DNA transformed colony was grown in 5 ml 
LB supplemented with 50 µg/ml of Kanamycin and incubated at 37ºC and 250 rpm. In the 
evening, 100 µl of cell suspension was inoculated in 400 ml or 25 ml of TB medium 
supplemented with Kanamycin. On day 2 in the morning, the OD was registered and a 
minicircle (MC) induction mix was prepared and 4 induction assays were performed. The first 
2 assays were performed as described by the manufacturer protocol and involved the 
combination of the MC induction mix, composed of 400 ml or 25 ml of LB supplemented with 
4% 1N NaOH and 0.1% of a 20 % L-Arabinose (Sigma) solution, with the overnight culture. 
In the third induction assay the 25 ml of the overnight culture was split in 2 flasks and one of 
the cultures was combined with 25 ml of MC induction mix while the second was combined 
with 12,5 ml of TB medium and 25 ml of MC induction mix. The fourth assay involved the 
division of the 25 ml of the overnight culture in 2 flasks and the addition of 25 ml of MC 
induction mix to each flask: one of the cultures was mixed with MC induction mix 
supplemented with 1% of 20% L-ara and the other was combined with MC induction mix 
supplemented with 2% of 20% L-ara. All the cultures were incubated at 30ºC with shaking at 
250 rpm for 7 hours or longer. The OD was registered every 2,5 hours and the presence and 
integrity of the MC-DNA and MC was assessed through agarose gel analysis.  
3.1.4. Preparation of E. coli competent cells 
A single colony of the desired E. coli strain (GT115 and ZYCY10P3S2T) was isolated 
and grown overnight, at 37ºC and 250 rpm, in a falcon containing 5 ml of LB.In the morning 
the Optical Density measured at 600 nm (OD) was measured and the appropriate volume of 
cell suspension was added to 20 ml of LB medium to start growth at OD = 0.1. , followed by 
incubation at 37ºC and 250 rpm. Simultaneously a TSS solution was prepared as follows: 10 
ml of 40 g/L LB, 1 ml of DMSO, 1 ml of 1M MgCl2, 2 g PEG8000 and H2O until 20 ml; the pH 
was adjusted to 6.5 and the solution was sterilized by filtration . When the OD of the cell 
suspension reached the value of 0.9, the content of the flask was divided into falcons and 
centrifuged at 1000 g for 10 minutes. The pellet was resuspended in 5 ml of cold TSS (0.1 V) 
and incubated on ice for 10 minutes. The suspension was divided into eppendorfs (100 
µL/eppendorf), and stored at -80ºC. 
3.1.5. Transformation of plasmids into E. coli 
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The transformation of E. coli competent cells with the desired plasmids (E. coli GT115 
with pCpGfree and pCpGfree-eGFP and E. coli XLlgold with PP-DNA) was performed using 
a Heat Shock protocol. Briefly, 2 µg of plasmid was added to 100 µl of cells, incubated for 15 
minutes on ice and at 42ºC for 1 minute. 900 µl of sterile LB medium supplemented with 
antibiotics (25 µg/ml of Zeocin for pCpGfree and pCpGfree-eGFP and 50 µg/ml of 
Kanamycin for MC-DNA) was then added to the mixture and a 40 minutes incubation, at 
37ºC and 250 rpm, was performed. Afterwards, the cells were centrifuged at 4000 rpm for 10 
minutes. The pellet was resuspendend in 100 µl of LB and plated overnight, at 37ºC, in LB 
Agar plates with respective antibiotics. Some colonies were then harvested and cultured 
overnight, at 37ºC and 250 rpm, in 5 ml LB falcons with antibiotics. The presence of the 
plasmids and their integrity was evaluated through agarose gel electrophoresis after a simple 
and a double enzymatic digestion of the pCpGfree and pCpGfree-eGFP with NheI, and NcoI 
and NheI respectively, and a simple enzymatic digestion of MC-PP with HindIII. 
3.1.6. Purification of plasmids 
The purification of plasmids (pCpGfree; pCpGfree-eGFP; pVAX-eGFP; PP-DNA and 
respective Minicircle (MC)) was performed using a miniprep kit (Promega), according to 
supplier’s protocol. 
3.1.7. Preparation of plasmid banks 
Colonies of transformed E. coli strains with the desired plasmids (E. coli GT115 
transformed with pCpGfree and pCpGfree-GFP; E. coli XLlgold and ZYCY10P3S2T 
transformed with PP-DNA) were harvested and inoculated in falcons containing 5 ml of LB 
supplemented antibiotics and grown overnight, at 37ºC and 250 rpm. Afterwards, 150 µl of 
cell suspension was inoculated into new 5 ml LB falcons with antibiotics in order to start the 
new growth with a OD=0.1. When the OD reached the value of 0.8 (after 4 hours of 
incubation at 37ºC and 250 rpm), the suspension was divided into criovials containing 200 µL 
of glycerol by adding to each vial 800 µL of the cell suspension. The vials were stored at - 
80ºC. 
3.1.8. Endotoxine free purification of plasmids 
Aliquots containing E. coli strains transformed with the  plasmids pVAX-eGFP and 
pCpGfree-eGFP were added to 2 L flasks with 250 ml of LB medium supplemented with 
antibiotics and allowed to grow overnight at 37ºC at 250 rpm. Plasmid DNA was then purified 
using an Endotoxin-free Plasmid DNA Purification kit (Machery-Nagel) according to 
manufacturer protocol and plasmid concentration was determined using a NanoDrop 
equipment (Digital Bio) by spectrophotometric measurements at 260 nm. 
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3.2. Cell lines 
3.2.1. Culture and expansion of HEK293T cells 
Criovials preserved at -80ºC, containing Human Embryonic Kidney (HEK) 293T cells 
(ATCC-LGC Nr: CRL-11268; Middlesex, UK)  were thawed by resuspending their content in 
6 ml of Dulbecco’s Modified Eagle Medium (DMEM, 1g/L Glucose, Gibco) supplemented with 
10% fetal bovine serum (FBS, Gibco) and 1% (v/v) penicillin/streptomycin (Gibco). The 
mixture was then centrifuged at 1250 rpm for 5 minutes, and the pellet was ressuspendend 
in 6 ml of DMEM (10% FBS, 1% PenStrep). The number of cells and their viability was 
determined by Trypan blue staining (Gibco). Afterwards 7.5 x 105 cells were cultured in 75 
cm2 T-flasks (FALCON®) (10000 cells/cm2) and grown in adherence, under static conditions, 
at 37ºC and 5% CO2-humidified atmosphere. Sub-confluent cells were collected and used for 
transfection with pCpGfree-eGFP and pVAX-eGFP. In brief, HEK293T cells were washed 
with 10 ml of Phosphate buffered saline (PBS) solution (Gibco) and harvested with 4 ml of 
Trypsin 0.25% (Gibco) after incubation for 3 minutes at 37ºC and 5% CO2-humidified 
atmosphere. The cells were then resuspendend in 6 ml of complete medium and centrifuged 
at 1250 rpm for 5 minutes and the pellet was resuspendend in culture medium. The number 
of cells and their viability was determined by Trypan blue staining and the cells were 
transfected by microporation. 
3.2.2. Culture and expansion of Neural Stem Cells 
CGR8-NS cells, derived from ES cell line CGR8 (Welcome Trust Centre for Stem Cell 
Research in Cambridge, United Kingdom) were thawed by swiftly submerging the criovials in 
a water bath at 37ºC and by resuspending the cells with RHB-A (Stem Cell Sciences) 
medium supplemented with 15 ng/ml of EGF and FGF-2 (Peprotech) and 1% of 
penicillin/streptomycin (100 µg/ml) (Gibco) or with DMEM/F-12 (Gibco) supplemented with 
0,8 g/ml of Glucose, 1% N-2 supplement (Gibco), 20 µg/ml insulin (Sigma), 1% of 
penicillin/streptomycin and 15 ng/ml of EGF, FGF-2 and B27 (Invitrogen). The mixture was 
centrifuged at 1000 rpm for 3 minutes and the pellet was resuspendend in 5 ml of culture 
medium. Cell viability was then assessed through Trypan blue assay. The cells were seeded 
in 25 cm2 T-flasks (10000 cells/cm2) and grown under static conditions at 37ºC and 5% CO2- 
humidified atmosphere. When the cells reached sub-confluence they were harvested with 1 
ml of Accutase (Sigma) and incubated at 37ºC and 5% CO2-humidified atmosphere for 3 
minutes. Afterwards they were resuspendend in growth factor supplemented medium and 
centrifuged at 1000 rpm for 3 minutes. The pellet was then resuspended in culture medium 
and the cell number and viability was assessed by Trypan blue staining. The cells were then 
used directly in transfection assays or cultured in T75 flasks and grown under static conditions 
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at 37ºC and 5% CO2-humidified atmosphere. When the T75 flasks exhibited a 70-80% cell 
confluence, NS cells were harvested and used for transfection. 
3.3. Gene transfection by microporation 
Cells were resuspendend in Resuspension buffer (RB; provided by the equipment 
manufacturer (Digital Bio)) or in Home Made Buffer (HMB; prepared at IBB/IST whose 
formulation is described elsewhere [79]) and incubated with a specific amount of vector DNA 
(pVAX-eGFP; pCPGfree-eGFP; MC-GFP, pCMV-GFP) on ice. Microporation was 
accomplished using a Microporator MP100 (DigitalBio/(Neon) Invitrogen). DNA amount is 
referred when appropriate and used within 200 000 CGR8-NS cells/ 10 µl of RB or HMB and 
150 000 HEK293T cells/10 µl of HMB. After microporation, the 10 µl of cell suspension was 
seeded as follows: HET293T cells were plated into a well of a 12- well culture plate with pre-
warmed medium without antibiotics; CGR8-NSCs for RT-PCR assays were seeded into a 24-
well culture plate with pre-warmed medium without antibiotics and CGR8-NSCs for cell 
proliferation kinetics analysis were added to 100 µl of pre-warmed medium without antibiotics 
and equally divided into 2 wells of a 24-well culture plate containing culture medium under 
the same conditions. Afterwards the cells were incubated at 37ºC and 5%CO2-humidified 
atmosphere for 24h after which the medium was replaced by complete medium. For the long 
term gene expression assays the cells maintained under the previously mentioned conditions 
for 10 days, and harvested on days 1, 3, 4, 7 and 10. On day 4 of cell proliferation kinetics 
assays (section 4.5.2) or on days 4 and 7 in RT-PCR assays (section 4.6.3) cells for the 
subsequent days were harvested and replated into two wells of  a 24- or 12- well plate, 
respectively.  The optimization assays were made with resuspension of CGR8-NS cells in 
RB and HMB and incubation with pVAX-eGFP and pVAX-eGFP or MC-GFP respectively. 
The cells were microporated using a different combination of programs and harvested and 
analyzed after incubation for 24h at 37ºC and 5%CO2-humidified atmosphere. In all the 
experiments, non-microporated (NM) cells were used as controls and each assay was 
repeated at least twice.  
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3.4. Analysis after transfection 
3.4.1. Fluorescence microscopy imaging 
Transfected and immunostained cells were visualized using a fluorescence optical 
microscope Leica DMI 3000B (Leica Microsystems GMbH) and digital images were obtained 
with a digital camera Nikon DXM 1200F. Fluorescence images were acquired with either 
green or red filters, depending on the purpose, and a minimum of 2 microscopic fields at 
100x, 200x and 400x magnification were scored. 
3.4.2. Flow cytometry  
The percentage of GFP expressing cells and level of expression were measured by flow 
cytometry in the FACSCalibur equipment (FACSCalibur Becton Dickinson). The cells in each 
well were harvested by transferring the medium to FACS tubes and adding Accutase to each 
well. After incubation at 37ºC and 5%CO2-humidified atmosphere, the cells were 
resuspendend in medium supplemented with growth factors and added to the FACS tubes. A 
centrifugation (1000 rpm, 3 minutes) was performed and the pellet was resuspendend in 100 
µl of culture medium. After counting, cells were fixed in 500 µl of 4% Paraformadehyde (PFA) 
and analyzed by flow cytometry. A minimum of 1000 events were gated and statistically 
evaluated by CellQuest software (BD Biosciences). 
3.4.3. Cell viability, recovery, yield and transfection efficiency 
The number of living and dead cells was assessed by Trypan blue exclusion method and 
cell viability, recovery and yield of transfection values were determined using the following 
equations: 
 
Cell Viability (%) =                                                   x 100 
 
Cell Recovery (%) =                x 100 
 
Yield (%) =                                        x 100 
  CAt corresponds to the number of viable transfected cells, CAc is the number of 
viable non-transfected cells (control) and CTc is the number of total cells (control). 
 
Total number of Viable 
Cells 
 
CTc   
 
%GFP+ cells x CAt 
    
 
CAc   
 
CAt    
 
Total number of cells 
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3.4.4. Cell proliferation kinetics  
CGR8-NSC were stained using PKH26 Red Fluorescent Cell Linker kit (Sigma) prior to 
transfection as described before [80]. Cells were then microporated with 2.0 x 1011 molecules 
of vector DNA (pVAX-eGFP; pCMV-GFP; Minicircle-GFP) as previously described (Section 
3.3.). Cells were analyzed by flow cytometry (FACSCalibur Becton Dickinson) and cell 
viability was calculated on days 1, 3, 4, 7 and 10 after transfection. The number of divisions 
or generations within a specific subset was assessed by analyzing the decrease of 
fluorescence overtime on a proliferation wizard module of the ModFit Software (Becton 
Dickinson) in the flow cytometer equipment. Non-Microporated cells were used as controls.  
3.4.5. Real Time PCR for quantification of vector DNA copies 
Quantitative Real-Time PCR (RT-PCR) was performed on microporated CGR8-NS cells 
incubated with a variable amount (0,1; 0,5; 0,8; 1; and 1,5 µg) of vector DNA (pVAX-eGFP; 
pCMV-GFP; MC-GFP) after 24h of incubation and on CGR8-NS cells incubated with  2.0 x 
1011 molecules of vector DNA (PVAX-eGFP; pCMV-GFP; Minicircle-GFP) on days 1, 4, 7 
and 10. PCR reactions were carried out in a Roche LightCyclerTM detection system using the 
FastStart DNA Master SYBR Green I kit (Roche, Basel) by amplification of a 108 bp 
sequence within the eGFP gene (forward primer: 5’- TCGAGCTGGACGGCGACGTAAA-3’ 
and reverse primer: 5’ – TGCCGGTGGTGCAGATGAAC – 3’; STABVida) and a 80 bp 
sequence within the GFP gene (forward primer: 5'-TGAACGGCGTGGAGTTCGAG-3' and 
reverse primer:  5'-GCTCTTCATCTTGTTGGTCATGCG-3'; STABVida). Each 20 µl of final 
reaction volume contained 2 µl of the 10x SYBR Green mixture, 0,4 µM of each primer, 3 mM 
of MgCl2, 2-5 µl of sample (corresponding volume to 20 000 NSC) and 9,4 µl of PCR grade 
water. The amplification of the sequences within the eGFP and GFP genes was carried out 
at 95ºC for 10 min, followed by 40 cycles of 10 s at 95ºC, 5 s at 55ºC and 7 s at 72ºC and at 
95ºC for 10 min, followed by 40 cycles of 10 s at 94ºC, 5 s at 53 ºC and 7 s at 72ºC 
respectively.  
Calibration curves were constructed by adding serial dilutions of vector DNA standards 
(pVAX-eGFP; pCMV-GFP; MC-GFP) to a suspension of NM CGR8-NS cells (20 000 cells 
per reaction). These samples were then mixed with the other PCR reagents as described 
above. One negative control was included in the analysis containing the same amount of NM 
cells and PCR grade water. 
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3.5. Differentiation of Neural Stem Cells 
Neuronal differentiation was accomplished as previously described by Spiliotopoulos et 
al [31]. Briefly, cells were transfected (1.5 x 105 – 2.0 x 105 cells/cm2) with 2.0 x 1011 
molecules of pVAX-eGFP and plated on a 6-well plate and incubated for 3 days at 37ºC and 
5%CO2-humidified atmosphere. Non-microporated cells and microporated cells without DNA 
were used as controls. Almost confluent cultures were then dissociated with Accutase, 
counted and plated on a 6-well plate using RHB-A medium supplemented with 1% B27, 0,5 
% N-2 Supplement and 10 ng/ml FGF-2,  at a density of 1.0 x 105 – 1.5 x 105 cells/cm2. After 
3 days at the previously mentioned conditions, cells were harvested with accutase, counted 
and plated at a density of 5 x 104 – 7.5 x 104 cells/cm2 on a Laminin (Sigma) – coated (3 
mg/ml for 4h at 37ºC) 24-well plate in medium composed of a 1:1 mixture of RHB-A and 
Neurobasal media (Invitrogen) supplemented with 0.5 % N-2 supplement, 1% B27, 10 ng/ml 
FGF-2 and 20 ng/ml BDNF (Invitrogen). After 3 days, the medium was replaced with medium 
composed of a 1:3 mixture of DMEM/F12 and neurobasal media containing 0.5% of N-2 
supplement, 1% B27, 6,7 ng/ml FGF-2 and 30 ng/ml BDNF. Three days later the medium 
was replaced with fresh media with a reduced amount of FGF-2 (5 ng/ml) and cells were 
maintained in these conditions for an additional 12 days with partial change of medium every 
3 days. Neuronal differentiation was then assessed by fluorescence microscopy imaging 
after staining with Alexa Fluor 488® labeled Neuronal Class III b-Tubulin (TUJ1) (Covance, 
dilution 1:2000) and DAPI (Sigma-Aldrich, dilituion 1:10000). 
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4. Results 
4.1. Production of CpG-free plasmids 
The commercial plasmid CpGfree (3049 bp) is a bacterial derived expression cassette 
which was modified in order to be completely devoid of CpG dinucleotides and DAM sites to 
prevent prokaryotic methylation. This plasmid contains an expression cassette, which 
comprises a modified promoter (CMV enhancer is combined with the EFI-a core promoter 
and 5’UTR containing a synthetic intron) and the late SV40 polyA signal, and sequences for 
expression in E. coli, such as, the R6Kγ ori, the EM2K promoter and the Zeocin selectable 
marker. Due to the presence of the modified R6Kγ ori, which can only be activated by the 
protein  π which is encoded by the pir gene, this plasmid was propagated and purified from a 
pir mutant E. coli GT115 strain that encodes a mutant protein π that recognizes the modified 
origin of replication, and allows plasmid replication (Fig.1A).   
 
 
 
 
 
 
 
 
 
  To construct the CpGfree-eGFP plasmid, the eGFP sequence was amplified from 
pVAX-eGFP through PCR. For this purpose the primers NcoI-GFP-Fwd and GFP-NheI-Rev 
were designed for the amplification and introduction of the NcoI and NheI restriction sites into 
the eGFP sequence. The resulting fragments were identified through gel agarose 
electrophoresis (Fig.1B), isolated and engineered into the MCS of pCpGfree by the action of 
T4 ligase. The construct was amplified in E. coli GT115 and the ligation was confirmed 
through agarose gel analysis after simple and double enzymatic digestion with NheI, and 
NheI and NcoI respectively, that originated one band of linearized pCpGfree-eGFP (≈3,7 kb) 
(Fig.1C, lane 2) and two distinct bands that corresponded to the CpGfree plasmid (≈3 kb) 
and the eGFP sequence (≈0,72 kb) (Fig.1C, lane 3).         
   
A) B) C) 
Figure 1: Agarose gel electrophoresis of pCpGfree and pCpGfree-eGFP construction.  
A) Confirmation of E. coli GT115 transformation with pCpGfree. Lane 1 represents supercoiled pCpGfree and 2 
the pCpGfree after restriction with NheI. B) Confirmation of eGFP amplification through PCR. Lanes 1 and 2 
represent the amplified eGFP fragment. C) Confirmation of the construction after simple and double enzimatic 
restriction. Lane 1 represents supercoiled pCpGfree-eGFP, 2 represents pCpG-eGFP after restriction with NheI 
(one band ≈3,7kb) and 3 represents pCpGfree and eGFP after double enzymatic restriction. M corresponds to 
NZYDNA III Ladder (NZYTech).   
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4.2. Long-term analysis of pCpGfree-eGFP transfected cells 
The CpGfree commercial plasmids were developed to allow high and sustained 
expression of transgenes in vitro and in vivo. These plasmids are completely devoid of CpG 
motifs that are recognized by TLR9 which trigger immune responses prompting transgene 
silencing. To assess the transfection efficiency of pCpGfree-eGFP and its maintenance 
overtime, HEK293T cells and CGR8-NC cells were microporated with 1 µg and 0.8 µg of 
pCpGfree-eGFP and pVAX-eGFP respectively, corresponding to the same number of 
molecules and equal to 2.4 x 1011 and 2.0 x 1011 respectively. Cells were analyzed at 
different points in time after transfection by flow cytometry and GFP expression was 
compared for cells transfected with pVAX-eGFP and pCpGfree-eGFP. 
 
 
 
 
 
 
 
 
Long term analysis of transfected HEK293T and CGR8-NS cells showed a lower 
percentage of pCpGfree-eGFP transfected cells and a faster decay of GFP expression 
compared with pVAX-eGFP transfected cells (Fig.3).  In pVAX-eGFP transfected HEK293T 
cells the GFP expression was maintained at high expression levels (over 70%) in the first 4 
days, and decreased until it reached its minimum level at day 12. In pCpGfree-eGFP 
transfected HEK293T cells the highest expression level was observed on day 1 (≈ 34%) and 
showed a fast decrease until it ceased on day 7 (Fig.2A). In CGR8-NS cells the expression 
was assessed for 3 days and is characterized by lower levels of GFP+ cells and faster GFP 
expression decay when compared with pVAX-eGFP transfected cells (Fig.2B).  These 
results indicate that pCpGfree-eGFP transient expression in vitro is fast diluted, suggesting 
that the problem might be within the pCpGfree formulation, more specifically, the modified 
promoter that might be weaker compared to the promoter present in pVAX-eGFP.  Due to 
these results, the use of pCpGfree-eGFP was discarded in further experiments.  
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Figure 2: Transfection efficiencies of HEK293T cells and CGR8-NS cells using pCpGfree-eGFP and pVAX-
eGFP.   
A) HEK193T cells were transfected with 1 µg of pDNA, using 1250V/20ms/1p. Cells were harvested on days 1, 4, 
7 and 12 and GFP expression was assessed through flow cytometry. The results are expressed as the mean ± 
SEM of 2 replicas of the same experiment. B) CGR8-NS cells were transfected with 0.8 µg of pDNA, using 
1500V/20ms/1p. Cells were harvested on days 1, 2 and 3 and GFP expression was assessed through flow 
cytometry. The results are expressed as the mean ± SEM of 2 replicas of the same experiment. Non-
microporated cells served as controls (not shown). 
- 24 - 
 
4.3. Induction assays for Minicircle production 
The minicircle production protocol developed by Systems Biosciences was prepared 
after the procedure of Kay et al. [75] and relies on the production of minicircles in an 
engineered E. coli strain that harbors an arabinose-inducible system that leads to the 
expression of фC31 integrase and the SceI endonuclease. Upon arabinose induction the full-
sized MC-DNA is separated into bacterial backbone (PP-DNA) and minicircle by the action of 
фC31 integrase, and the PP-DNA is degraded by the action of SceI endonuclease 
(Supplementary Fig.2).  
To test minicircle induction conditions, four (I1, I2, I3 and I4) distinct induction assays 
were performed. In all the experiments, a PP-DNA engineered E. coli ZYCY10P3S2T colony 
was grown in LB on day 1 and incubated overnight in TB medium and the OD600 was 
registered in the morning before starting induction. According to the manufacturers protocol, 
on day 2 in the morning, the OD600 should be around 4 or 5, however, in all the performed 
experiments, the OD600 of the overnight culture was above 8 ( OD600: I1= 9.4, I2 = 9, I3 = 
8.6, I4 = 8.5) (Table 1). The first two induction assays (I1 and I2) were performed as 
described by the protocol, the OD600 was registered at specific points in time and the 
induction efficiency was evaluated through gel agarose electrophoresis after purification of 
DNAs as described in section 3.1.6. The results of both assays indicate that the culture 
reaches the growth stationary phase after 5 hours of induction, as described by the protocol, 
at an OD600 of around 7 (Table 1). However, the induction was not efficient, and in both 
cases, it was not possible to produce purified minicircle (at I1 it was not possible to identify 
any band that corresponded to minicircle, and at I2 production of minicircle was detected, 
however, the presence of full-sized PP-DNA was also identified) (Fig. 3, I1 and I2). 
 
 
 
I1 I2 I3 I4 
Time (h) OD600 Time (h) OD600 Time (h) 
OD600 
Time (h) 
OD600 
C1 C2 C1 C2 
0* 9.4 0* 9 0* 8.6 0* 8.5 
0 6.2 3 6.2 0 5.6 2.6 0 3.2 3.5 
2.5 6.7 4.5 7.1 2.5 6.4 3.7 5 5.5 5.5 
5 7.3 6 7 5 7.2 4.7 7 5.8 6 
7 7.3 9.5 6.5 7 6.5 4.7 24 6.5 6.7 
Table 1: OD600 values for the induction assays for the production of minicircles. 
 I1, I2, I3 and I4 represent the 4 assays performed and 0* corresponds to the OD600 value for the overnight 
culture on day 2 before induction, and the subsequent values were registered at specific hours throughout the 
induction.  
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To test if the inefficient production of minicircles was due to starvation or insufficient 
arabinose quantity, two other induction experiments were performed with modifications in the 
provided procedure. In the third induction experiment (I3), to test the hypothesis of culture 
starvation, the overnight culture was split in two flasks and while one of the flasks was 
combined with MC induction mix (C1), the second was combined with fresh TB medium and 
MC induction mix (C2), and in the fourth experiment (I4), to test the effect of arabinose 
concentration, the overnight culture was split into two flasks and each was blended with MC 
induction mix with a 10- or 20- fold increase (C1 and C2 respectively) in the arabinose 
concentration suggested by the manufacturers protocol. 
 
 
 
 
 
 
 
 
The results indicate that the stationary growth phase was achieved 5 (I3, C1 and C2) 
and 7 hours (I4, C1 and C2) after the start of induction at an OD600 of around 5 and 7 
(Table 1). The agarose gel analysis shows that, even after providing more nutrients to the 
culture (I3) and increasing the arabinose concentration in the induction mix (I4) it was not 
possible to efficiently produce and purify uncontaminated minicircles (Fig.3, I3 and I4) 
because even after 24h of culture a band of parental plasmid was observed. Moreover, it 
seems that a low amount of corresponding minicircle was obtained. The obtained results 
suggest that the inefficient production of uncontaminated minicircles is a result of 
uncontrolled overgrowth, as it was evidenced by the high OD600 obtained in all the induction 
assays, and subsequent progressive cellular death of the PP-DNA engineered E. coli 
cultures caused by the lack of nutrients and space to sustain the high concentration of 
bacteria in the cultures.   
 
Figure 3: Agarose gel electrophoresis 
of the Minicircle induction assays. 
 I1) analysis of MC induction at 5 and 7 
hours; I2) analysis of MC induction at 
hours 3, 4.5 and 9.5; I3) analysis of MC 
induction of cultures 1 and 2 at hours 5 
and 7; I4) analysis of MC induction of 
cultures 1 and 2 at hours 5 and 24; In all 
the assays M corresponds to NZYDNA III 
Ladder (NZYTech) and 0h represents the 
isolated full-sized PP-DNA before the 
start of minicircle induction.  
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4.4. Optimization of microporation conditions in NSC 
4.4.1. Optimization of microporation conditions using RB 
To determine the appropriate microporation conditions to achieve higher transfection 
efficiencies in CGR8-NSCs resuspended in RB, three different optimization assays were 
performed. In the first optimization assay 200,000 cells were resuspended in RB, 
microporated with 1 µg of pVAX-eGFP and transfected using different voltages: 1300, 1400, 
1500, 1600 and 1700 V, with 20 ms of pulse duration and 1 pulse. Cells were analyzed after 
24h for cell viability (Fig. 4A) and recovery (Fig. 4B). Yield of Transfection and GFP+ cells 
were determined by flow cytometry (Fig. 4C and D).  
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Figure 4: Transfection of CGR8-NSC resuspended in RB and microporated using 5 different voltages with 
20 ms of duration and 1 pulse.  
CGR8-NSCs were transfected with 1 µg of pVAX-eGFP and analyzed 24h after microporation by trypan blue 
exclusion method for A) cell viability, B) Cell recovery and flow cytometry for C) yield of transfection, and D) 
Percentage of cells expressing GFP; NM cells were used as controls (Control viability ≈92%, not shown) and the 
results are expressed as mean ± SEM of two independent experiments. 
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High cell viabilities and recoveries were obtained when using 1300 V (cell viability ≈93%; cell 
recovery ≈94%) and 1500 V (cell viability ≈86%; cell recovery ≈92%), however, the highest 
yield of transfection and percentage of positive GFP cells were obtained with 1500 V (Yield 
≈72%; GFP+ ≈60%).  Overall, the results indicate that 1500 V might be an appropriate voltage 
to transfect CGR8-NS cells when using RB as electroporation buffer, therefore this voltage 
was determined for the posterior transfection assays.  
 In the second optimization assay 200,000 cells were resuspended in RB, 
microporated with 1 µg of pVAX-eGFP and transfected using different pulse durations (20 ms 
and 30 ms) with 1500 V as predetermined voltage and 1 pulse. Cells were analyzed after 
24h for cell viability and recovery, percentage of GFP+ cells (Supplementary Fig. 3A) and 
yield of Transfection (Supplementary Fig. 3B). Cell viability and recovery was higher for 
cells transfected using 20 ms of pulse duration (Cell viability and recovery ≈ 85-90%) 
compared to cells transfected using 30 ms (Cell viability ≈ 47%; Cell recovery ≈ 27%). The 
obtained results for the level of GFP+ cells and yield of Transfection were consistent with the 
acquired cell viabilities and recoveries showing higher levels (GFP+ cells ≈60%; Yield ≈52%) 
when using 20 ms as pulse duration. Given the obtained results, it is evident that using 
shorter duration pulses is more beneficial to obtain higher transfection efficiencies. 
Additionally, a new combination of settings, based on the decreasing of pulse duration from 
20 to 10 ms and the increase of the number of pulses from 1 to 2, was tested, however, 
although results were slightly better than the ones obtained with 30 ms, they were not as 
good as the ones obtained with 1500V, 20 ms and 1 pulse (data not shown). With the 
previously described optimization assays it was possible to determine that, when using the 
electroporation buffer RB, the preferred condition to transfect CGR8-NS cells by 
microporation is 1500 V with 20 ms of pulse duration and 1 pulse.  
 The third optimization assay was performed to determine the ideal amount of plasmid 
vector to transfect CGR8-NS cells. For this purpose, 200,000 cells were resuspended in RB 
and microporated using increasing amounts of pVAX-eGFP (0.5, 0.8, 1.0 and 1.5 µg) at 
1500V/20ms/1p as microporation condition. Cells were analyzed after 24h for cell viability 
(data not shown) and recovery (Fig. 5B), percentage of GFP+ cells (Fig. 5A) and yield of 
Transfection (data not shown).   
The increase in DNA amount caused a significant decrease in cell viability (from 92 to 
59%, data not shown) however, the highest cell recovery level was obtained when using 0.8 
µg of pVAX-eGFP (≈ 86%).  These results were also evident when analyzing the yield of 
transfection that showed higher values for cells transfected with 0.8 µg of pDNA (≈ 40%). On 
- 28 - 
 
the other hand, the increase of DNA amount didn’t seem to greatly affect the level of GFP 
transfected cells that showed similar values (≈50%) in all the tested amounts. Therefore, the 
pDNA quantity that showed the better results, 0.8 µg, was chosen for the subsequent 
experiments and studies.  
  
 
 
 
4.4.2. Optimization of microporation conditions using HMB 
 Another optimization assay was performed to determine the appropriate microporation 
conditions when resuspending CGR8-NS cells in another electroporation buffer. For this 
effect CGR8-NS cells were resuspended in HMB, a buffer that was previously prepared at 
the laboratory and proven to be efficient in microporation of HEK293T cells [79], and 
transfected with 2.0 x 1011 molecules of MC-GFP and pVAX-eGFP, which corresponded to 
0.5 and 0.8 µg of vector DNA respectively, to avoid differences related to the number of 
vectors supplied. Cells were then microporated using different voltages (1600, 1700, 1800 
and 1900V) with 20 ms and 1 pulse as microporation conditions. After 24h, the cells were 
analyzed and results were obtained for cell viability and recovery (data not shown), levels of 
GFP+ cells and yield of Transfection (Fig. 6). 
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Figure 5: Transfection of CGR8-NSCs ressuspended in RB and transfected using different amounts of 
pDNA and 1500V/20ms/1p as microporation parameters.  
CGR8-NSCs were transfected with 0.5, 0.8, 1.0 and 1.5 µg of pVAX-eGFP and analyzed 24h after 
microporation; A) % GFP
+
 cells was assessed by flow cytometry and B) Cell recovery was assessed by trypan 
blue exclusion method. NM cells were used as controls (Control viability ≈92%) and the results are expressed as 
mean ± SEM of two independent experiments. 
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 The obtained results show that cell viability and recovery slightly decrease with higher 
voltages for MC-GFP transfected cells (cell viability from ≈92 to 82%; cell recovery from ≈97 
to 83%) and plummet for cells transfected with pVAX-eGFP (cell viability from ≈84 to 63%; 
cell recovery from ≈65 to 49%). As for levels of GFP+ cells and yield of Transfection, the 
values rose significantly with the increase of the voltage until 1800 V, with GFP+ levels 
ranging from 45 to 75% in MC-GFP transfected cells and 29 to 58% in pVAX-eGFP 
transfected cells and yields from 44 to 69% in MC-GFP transfected cells and 16 to 47% in 
pVAX-eGFP transfected cells. However, when using 1900V as microporation setting the 
levels of GFP transfected cells stabilized (Fig. 6A) and the yield of Transfection decreased 
(Fig. 6B) most probably as a result of the lower cell viabilities and recoveries obtained with 
this voltage. These results suggest that for resuspension of CGR8-NS cells in HMB, the 
preferred microporation condition is 1800V, 20 ms and 1 pulse.   
4.4.3. Comparison of transfection efficiency using RB and HMB 
To compare the effect of the microporation buffer in cell viability, recovery and overall 
yields, CGR8-NS cells were resuspended in RB or HMB and transfected with 2.0 x 1011 
molecules of MC-GFP, pCMV-GFP and pVAX-eGFP (0.5 µg of MC-GFP and 0.8 µg of 
pCMV-GFP and VAX-eGFP), , using the fixed microporation settings for cells ressuspended 
in RB, 1500V/20ms/1pulse. Cells were analyzed after 24h for cell viability (data not shown) 
and recovery and percentage of GFP+ cells (Fig. 7).  
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Figure 6: Transfection of CGR8-NSCs resuspended in HMB and microporated using different voltages 
with 20 ms of duration and 1 pulse.  
CGR8-NSCs were transfected with 2 x 10
11 
of MC-GFP and pVAX-eGFP, and analyzed 24h after microporation 
by trypan blue exclusion method and flow cytometry; A) Percentage of GFP
+
 cells and B) Yield of Transfection. 
NM cells were used as controls (Control viability ≈ 82%, not shown) and the results are expressed as mean ± 
SEM of three independent assays. 
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 Slightly higher viabilities are achieved when using HMB as resuspension buffer (MC-
GFP: ≈92%; pCMV-GFP: ≈87%; pVAX-eGFP: ≈87%) compared to cells resuspended in RB 
(MC-GFP: ≈91%; pCMV-GFP: ≈79%; pVAX-eGFP: ≈77%). The same pattern of results is 
obtained when evaluating cell recoveries of cells transfected with each vector. Cell recovery 
was higher for cells resuspended with HMB, regardless of the used vector (Fig. 7B), 
whereas, higher levels of GFP transfected cells were obtained when resuspending cells in 
RB, achieving a maximum of 62% for MC-GFP transfected cells, 52% for pCMV-GFP 
transfected cells and 38% for pVAX-eGFP transfected cells (Fig. 7A).  
 These results suggest that RB, a buffer of unknown composition, yields higher 
conductivity, and, as a consequence, might cause increased cellular death. On the other 
hand, the use of HMB as electroporation buffer, allows a more sustained survival of the cells, 
however, to achieve levels of GFP expression comparable to those obtained with RB, it is 
necessary to increase the voltage of the microporation conditions as it was evidenced by the 
obtained results with HMB and shown in section 4.4.2. 
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Figure 7: Comparison of Transfection efficiencies of CGR8-NSCs ressuspended in RB and HMB and 
transfected with different vectors (MC-GFP; pCMV-GFP; pVAX-eGFP) and transfected using 
1500V/20ms/1p as microporation parameters.  
CGR8-NSCs were transfected with 2.0 x 10
11
 molecules of MC-GFP, pCMV-GFP and pVAX-eGFP, and 
analyzed 24h after microporation A) Percentage of GFP
+
 cells was assessed by flow cytometry and B) Cell 
Recovery was assessed by trypan blue staining. NM cells were used as controls (Control viability > 92%, not 
shown) and the results are expressed as mean ± SEM of four replicas of one experiment. 
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4.5. Effect of different gene vectors on NSC transgene expression 
4.5.1. Long-term analysis of transfected cells 
One of the major factors affecting non-viral gene transfer is the nature of the vector 
Therefore, to assess the effect of different gene vectors on CGR8-NS cells transgene 
expression, cells were transfected using different vectors, more specifically, MC-GFP, 
pCMV-GFP (both from Plasmid Factory) and pVAX-eGFP, which have different contents of 
CpG dinucleotides, that is, ~ 7% of pCMV-GFP and pVAX-eGFP backbone contain CpG 
motifs and ~ 6% of MC-GFP yield these dinucleotides (Supplementary Table 1).  
To evaluate and compare cell proliferative capacity, maintenance and vector stability 
overtime, CGR8-NS cells were resuspended in RB and transfected with 2.0 x 1011 molecules 
of MC-GFP, pCMV-GFP and pVAX-eGFP using the optimized microporation conditions for 
RB, 1500V, 20 ms and 1 pulse. Cells were cultured for 10 days in 24-well plates and replated 
on day 4 to new 24-well plates when they reached confluence. The analysis was performed 
on days 1, 3, 4, 7 and 10 by trypan blue exclusion method and flow cytometry and on day 1 
the cells were visualized by fluorescence microscopy.  
 Long term analysis showed that cells transfected with MC-GFP exhibit higher numbers 
of GFP expressing cells when compared to CGR8-NS cells transfected with pCMV-GFP and 
pVAX-eGFP. Among the three vectors the latter shows lower levels of GFP+ cells. 
Nonetheless, cells transfected with MC-GFP and pCMV-GFP showed a similar  profile, i.e., 
the number of cells expressing the transgene reached its maximum on day 3 (MC-GFP: 
≈75%; pCMV-GFP: ≈ 58%) and slowly declined until day 10 where MC-GFP transfected cells 
still displayed 20% of GFP+ cells compared to the 6% of GFP+ cells exhibited by transfection 
with pCMV-GFP. On the other hand, transfection of CGR8-NS cells with pVAX-eGFP 
showed that the maximum of GFP+ cells is achieved on day 1 (≈ 38%) and slowly declines 
until it almost ceases on day 10, where only 1% of the cells still express the transgene (Fig. 
8A). The difference between both plasmids (pCMV-GFP and pVAX-eGFP) that might explain 
the differences in GFP expression relies on the GFP gene and most probably the sequence 
provided by plasmid factory gives rise to a brighter protein or encompass other sequences 
that increase gene expression levels.  
 The analysis of cell viabilities demonstrated that, when transfected, CGR8-NS cells are 
able to maintain a relatively stable survival rate. The results show that the highest cell 
viability levels were obtained upon MC-GFP transfection, which exhibit cell viability values of 
around 90% throughout the analyzed days, when compared with cells transfected with 
pCMV-GFP and pVAX-eGFP whose viabilities are maintained around 80% and 70% 
respectively. In pVAX-eGFP transfected cells, cell viability was only analyzed until day 4.  On 
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day 4, due to culture confluence, a new passage was performed; however, the proliferation 
rate of transfected and non-transfected cells was probably influenced and by day 7, instead 
of adhering to the plate floor, the cells formed neurospheres.  While MC-GFP and pCMV-
GFP transfected CGR8-NSCs recovered, the ones transfected with pVAX-eGFP were not 
able to recuperate and culture was only maintained until this day (Fig. 8B).  
 
 
 
 
 The fluorescence images obtained after 24h of transfection show that MC-GFP enables 
efficient gene delivery to CGR8-NS cells, displaying a high number of fluorescent cells and 
fluorescence intensity, without affecting their morphology that maintained their characteristic 
bipolar form (Supplementary Fig. 4A and B). In comparison, CGR8-NS cells transfected 
with pCMV-GFP (Supplementary Fig.4C and D) and pVAX-eGFP (Supplementary Fig. 4E 
and F) exhibit lower levels of transfection and transgene expression evidenced by the lower 
number of cells that display high fluorescence intensity. By the images it is also evident that 
although pCMV-GFP transfected cells maintain bipolar morphology, transfection with pVAX-
eGFP impairs the survival rate and morphological characteristics of CGR8-NS cells. When 
compared to the others, these cells are smaller and rounder and present in a much lower 
number, hinting that their recovery rate is much slower.   
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Figure 8: Long-term analysis of transfected CGR8-NSC for 10 days.  
CGR8-NSCs were ressuspended in RB and transfected with 2.0 x 10
11
 molecules of MC-GFP, pCMV-GFP and 
pVAX-eGFP using 1500V/20ms/1p as microporation conditions. Cells were analyzed on days 1, 3, 4, 7 and 10 
after microporation. A) Percentage of GFP expressing cells was assessed by flow cytometry and B) Cell Viability 
was assessed through trypan blue assay. NM cells were used as controls (Control viability from 91 to 97%) and 
the results are expressed as mean ± SEM of two independent experiments. 
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 Overall, these results indicate that gene delivery is most efficient when using MC-GFP 
as a delivery vector. Upon transfection with this vector it is possible to achieve high 
transgene expression without compromising their survival and morphology and for a longer 
period of time when compared with transfection with pCMV-GFP and pVAX-eGFP. Another 
relevant point is the difference found in expression levels and cell viability of pCMV-GFP and 
pVAX-eGFP transfected cells. Both vectors are plasmids with similar CpG content therefore 
the discrepancy found between the two vectors might be explained by the level of purification 
of both plasmids. Indeed the method of purification of pCMV-GFP accomplished by Plasmid 
Factory, might be more efficient than the Endotoxine Purification protocol used in-house to 
purify pVAX-eGFP. 
4.5.2. Cell division kinetics analysis of transfected cells 
To analyze the effect of each vector (MC-GFP, pCMV-GFP and pVAX-eGFP) on CGR8-
NSC proliferation rate, cells were labeled with PKH67 and then transfected with 2.0 x 1011 
molecules of each vector using 1500V, 20 ms and 1 pulse as microporation settings and 
cultured for 7 days. Non-microporated cells and transfected cells were then compared in 
terms of their cell division kinetics by flow cytometry.  
Non-microporated cells and transfected cells showed a similar division profile on days 1, 
3 and 7, independently of the used vector. On day 3 all the cells had undergone cell division 
and there weren’t already any nondividing cells (Parent) present in culture. On the other 
hand, on day 4, while MC-GFP and pCMV-GFP transfected cells showed a division rate 
similar to the one of non-microporated cells, displaying most of the cells at Generation 4 (Fig. 
9A, B and C), pVAX-eGFP transfected CGR8-NSC showed a small delay on cellular division 
exhibiting most of the cells evenly distributed at Generation 3 (≈ 39%) and 4 (≈ 36%)(Fig. 
9D). By day 7, regardless of the vector, transfected cells were distributed around Generation 
3 and 8 in rates similar to the ones found in the controls, an effect that might be due to the 
performed passage of the cells on day 4, which might have affected the proliferation rates of 
both transfected and non-transfected CGR8-NSC. These results suggest that, in CGR8-
NSCs, the proliferation kinetics is not influenced upon transfection with MC-GFP and pCMV-
GFP, but a slight delay appears when transfecting with pVAX-eGFP.  
The comparison of the demonstrated proliferations with the transfection efficiencies of 
each vector show that, despite exhibiting higher numbers of cells presenting GFP 
fluorescence, the proliferation kinetics of cells transfected with MC-GFP and pCMV-GFP was 
not affected, even on days 3 and 4, when transgene expression reached its peak. 
Conversely, upon transfection with pVAX-eGFP a small delay in the division kinetics was 
detected even when the number of GFP expressing cells was declining. These combined 
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results suggest that, unlike MC-GFP and pCMV-GFP, the use of pVAX-eGFP as transgene 
vector might cause a slight alteration of the division rate of CGR8-NS cells.   
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Figure 9: Cell division kinetics of transfected CGR8-NSC for 7 days.  
CGR8-NSCs were labeled with PKH67 and data was acquired by flow cytometry at days 1, 3, 4 and 7. Each bar 
represents the percentage of cell in each doubling generation, along 7 days. A) Non-microporated cells; B) Cells 
transfected with MC-GFP; C) Cells transfected with pCMV-GFP; D) Cells transfected with pVAX-eGFP. Results 
are expressed as mean ± SEM of two independent assays. 
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4.6. Quantification of plasmid and minicircle copies in the nucleus 
4.6.1. Calibration curves 
 To determine the number of plasmid and minicircle copies in the nucleus a standard 
curve for each vector was generated by spiking 20,000 of non-microporated CGR8-NSC with 
increasing amounts of vector DNA.  A linear working range covering from 3 (61 molecules 
MC-GFP/cell; 39 molecules pCMV-GFP/cell; 37 molecules pVAX-eGFP/cell) to 30,000 pg 
(6.1 x 105 molecules MC-GFP/cell; 3.9 x 105 molecules pCMV-GFP; 3.7 x 105 molecules 
pVAX-eGFP/cell) was obtained for each vector (Fig 10). These curves allow the 
quantification of vector DNA in the nucleus and the obtained CT of a sample corresponds to a 
determined number of copies.   
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Figure 10: Calibration curves for relative 
quantification of vector/nucleus.  
The threshold cycle (CT) was obtained for a 
range of concentrations (3 to 30000pg – plotted 
as log (mass)) of A) pVAX-eGFP, B) MC-GFP 
and C) pCMV-GFP added to 20000 NM CGR8-
NS cells. The values represent means of CTs 
obtained from three different experiments. The 
fitted linear regression equation and the R
2
 
value are shown in each graph.    
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4.6.2. DNA vector amount vs. gene expression 
Nuclear uptake of vector DNA is usually impaired by extra- and intracellular barriers and 
is highly influenced by the type of used vector and delivery method, therefore, the obtained 
transgene expression is never a result of the whole amount of transfected vector copies. To 
determine the optimal dose of vector DNA from which transgene expression achieves its 
maximum level, CGR8-NS cells were resuspended in HMB and transfected with increasing 
amounts of vector DNA (0.1, 0.5, 0.8, 1.0 and 1.5 µg of MC-GFP, pCMV-GFP and pVAX-
eGFP). Cells were analyzed after 24h by trypan blue exclusion method and flow cytometry 
and the number of vector DNA copies that reached the nucleus was determined using a 
standardized quantitative PCR (qPCR) assay.   
 
 
 
 Once again, the results show that the highest number of transfected cells and cell 
viability   are obtained upon transfection with MC-GFP (Fig. 11).  Common to all the used 
vectors is the fact that cell viability slowly decreases with the increase of the DNA amount, 
ranging from 83 to 71%, 72 to 58% and 66 to 51% in MC-GFP, pCMV-GFP and pVAX-eGFP 
transfected cells respectively (Fig.11A), and, as depicted from Fig. 11B,  transfection with 
0.8 µg of MC-GFP, pCMV-GFP and pVAX-eGFP result in 68, 44 and 45% of GFP+ cells 
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Figure 11: Transfection of CGR8-NS with different amounts of vector DNA.  
CGR8-NSCs were ressuspended in HMB and transfected with 0.1, 0.5, 0.8, 1.0 and 1.5 µg of vector DNA (MC-
GFP; pCMV-GFP; pVAX-eGFP). Cells were analyzed after 24h and A) Cell Viability was assessed by trypan blue 
exclusion method and B) % GFP
+
 cells was obtained by flow cytometry analysis. NM cells were used as controls 
(Control viability ≈ 84%, not shown) and results are expressed as mean ±SEM of three independent experiments.  
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respectively,  suggesting that the DNA amount which gives rise to the highest number of 
GFP expressing cells is 0.8 µg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In comparison, the quantification of vector DNA in the nucleus showed that, 
regardless of the vector, the number of copies inside the nucleus increase with the augment 
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Figure 12: Quantification of vector DNA/nucleus and GFP expression intensity of CGR8-NS cells 
transfected with different amounts of vector DNA. 
CGR8-NSCs were ressuspended in HMB and transfected with 0.1, 0.5, 0.8, 1.0 and 1.5 µg of each vector and 
analyzed after 24h. The quantification of A.1) MC-GFP, B.1) pCMV-GFP and C.1) pVAX-eGFP inside each 
nucleus was assessed by RT-PCR and the Mean Fluorescence Intensity (MFI) of A.2) MC-GFP, B.2) pCMV-GFP 
and C.2) pVAX-eGFP was determined through flow cytometry. NM cells were used as controls and the results 
are expressed as mean ± SEM of three independent assays.  
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of DNA amount. Cells transfected with MC-GFP, pCMV-GFP and pVAX-eGFP exhibited an 
increase from 34,000 to 178,000, 14,000 to 560,000 and 5,100 to 51,000 copies of vector 
DNA/ cell respectively (Fig. 12A.1,B.1 and C.1).  On the other hand, when comparing with 
the MFI values it is clear that the increase in nuclear uptake of vector DNA is not correlated 
with the transcription of each transgene, indicating that, although the number of 
copies/nucleus increases with the amount of DNA, the expression of these vectors stabilize 
and eventually decrease with the highest amounts of provided DNA (Fig. 12A.2, B.2 and 
C.2).  The differences between nuclear uptake of each vector DNA and GFP expression can 
be confirmed by the transfection of CGR8-NS cells with the lowest amounts of DNA, (from 
2.02 x 105 to 1.62 x 106 copies of MC-GFP, 1.31 x 105 to 6.54 x 105 copies of pCMV-GFP 
and 1.23 x 105 to 9.87x105 copies of pVAX-eGFP per cell) which showed that the percentage 
of vector DNA that enters the nucleus is similar when using MC-GFP and pCMV-GFP as 
transfection vectors (around 10% using the lowest amount of DNA) , and lower upon pVAX-
eGFP usage (around 4% with the lowest amount of DNA) (Table 2), however, the highest 
expression levels are obtained with MC-GFP that show MFI values ranging from 660 to 
2265, when compared to pCMV-GFP and pVAX-eGFP whose values range from 746 to 1484 
and 145 to 524 respectively (Fig. 12A.2, B.2 and C.2).  For the highest amounts of pCMV-
GFP, the obtained results showed higher percentages of nuclear uptake of this plasmid 
(Table 2, Fig. 12B.1), however, the obtained SEM values are also very high therefore further 
experiments need to be performed to confirm or refute the obtained results.  
 
 
  
Dose of vector/cell % DNA inside the nucleus after 24 h (± 
SEM) No. Molecules Mass (µg) 
Minicircle-
GFP 
2.02E+05 0.1 10.82 ± 4.79 
1.62E+06 0.8 5.78 ± 1.87 
2.02E+06 1.0 6.17 ± 1.35 
3.03E+06 1.5 5.89 ± 1.11 
pCMV-GFP 
1.31E+05 0.1 10.37 ± 2.66 
6.54E+05 0.5 5.44 ± 1.49 
1.31E+06 1.0 21.36 ± 12.21 
1.96E+06 1.5 28.59 ± 14.19 
pVAX-eGFP 
1.23E+05 0.1 4.14 ± 1.84 
6.17E+05 0.5 1.24 ± 0.31 
9.87E+05 0.8 2.40 ± 1.04 
1.23E+06 1.0 2.38 ± 0.71 
1.85E+06 1.5 2.75 ± 0.70 
Table 2: Percentage of vector DNA inside the nucleus of CGR8-NS cells transfected with different 
amounts of MC-GFP, pCMV-GFP and pVAX-eGFP (results are expressed as Mean ± SEM of 3 independent 
experiments). 
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Altogether, these results suggest that saturation in transgene expression in CGR8-NS 
cells is achieved upon transfection with around  0.8 µg of vector DNA and that MC-GFP is 
the vector that is more efficiently expressed and the one that less affects cell survival. A 
comparison of the data obtained for MC-GFP and pCMV-GFP indicate that the highest 
percentage of CpG motifs in the latter might be the main factor affecting transgene 
expression which can be translated as a silencing triggered by the recognition of CpG motifs 
and posterior degradation of the plasmids.  
4.6.3. Dilution kinetics of DNA vector along cell division 
 Dilution kinetics of vector DNA was assessed by quantifying overtime the number of 
vector copies present inside the nucleus of transfected cells. For this purpose CGR8-NS 
cells were resuspended in HMB and transfected with 2.0 x 1011 molecules of each vector 
using 1800V, 20 ms and 1 pulse as microporation conditions. Cells were cultured for 10 days 
and passaged on days 4 and 7 and analyzed at different points in time after transfection by 
trypan blue assay, flow cytometry and by quantification of vector copies in the nucleus was 
assessed by qPCR. 
 
 
 
 With the obtained results it’s possible to compare the transfection efficiency of cells 
resuspended in HMB and RB overtime. Common to both experiments is that MC-GFP is the 
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Figure 13: Long-term analysis of transfected CGR8-NS cells, using HMB along 10 days.  
CGR8-NSCs were ressuspended in HMB and transfected with 2.0 x 10
11
 molecules of MC-GFP, pCMV-GFP and 
pVAX-eGFP and analyzed on days 1, 4, 7 and 10.  A) Cell viability was assessed by trypan blue staining and B) 
Percentage of GFP
+
 cells was assessed by flow cytometry analysis. NM cells were used as controls and the 
results are expressed as mean ± SEM of three independent experiments. 
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vector that exhibits the highest cell viability values and the one that gives rise to the highest 
percentage of GFP+ cells, however, when using HMB as electroporation buffer, there are 
some differences related to the initial values of cell viability and in the GFP expression decay 
throughout the analyzed days. Due to the fact that, to obtain higher number of GFP+ cells 
microporation needs to be performed with higher voltages, the initial cell viability is lower 
(MC-GFP ≈61%, pCMV-GFP ≈56%, pVAX-eGFP ≈43%) when compared to the one obtained 
with RB (section 4.5.1, Fig. 8), however, it slowly increases (MC-GFP from 61 to 89%, 
pCMV-GFP from 56 to 88% and pVAX-eGFP from 43 to 70%) with the decrease of GFP 
expression levels (Fig. 13A). Moreover, although the percentage of GFP+ cells decay profile 
is similar to the one obtained in the previously described long-term experiment, the obtained 
values are similar at first but decrease faster. For example, while in the first long-term 
experiment, on day 10 MC-GFP transfected cells still exhibited 20% of GFP+ cells, in this 
experiment, by day 10 the number of GFP+ cells is almost inexistent (Fig. 13B). 
 The level of GFP expression was also correlated with the number of vector copies/cell 
(Table 3). On day 1, after transfection there was a higher number of pCMV-GFP copies 
inside the nucleus (pCMV-CMV/cell = 195901) when compared to the other vectors. In 
comparison the number of copies/nucleus of MC-GFP transfected cells was slightly lower 
(MC-GFP/cell = 146414) and significantly lower in pVAX-eGFP transfected cells (pVAX-
eGFP/cell = 12036). On the other hand, when comparing the MFI values on the first day, it is 
evident that even though less copies of MC-GFP were detected per nucleus, the expression 
levels are higher upon transfection with this vector.  The analysis of the number of vector 
copies/nucleus on the other days show that MC-GFP dilution upon cell division is lower than 
the pDNAs and by day 4 and 7, the number of MC-GFP copies/nucleus and the transgene 
expression level is much higher when compared to the other vectors (Table 3), indicating 
that MC-GFP is the vector that persists more time inside the nucleus thus allowing a more 
sustained expression. 
 
 
 
 
Minicircle-GFP pCMV-GFP pVAX-eGFP 
Time 
 (days) 
MFI Vector/cell MFI Vector/cell MFI Vector/cell 
1 
1808 ± 232 
146414 ± 
20776 
1089 ± 
217 
195901 ± 98823 163 ± 62 12036 ± 368 
4 606 ± 249 11809 ± 1301 455 ± 113 1845 ± 1018 45 ± 12 1403 ± 1099 
7 100 ± 42 2802 ± 1168 47 ± 8 321 ± 277 1,60 ± 1 123 ± 106 
Table 3: Long-term quantification of vector DNA/nucleus and GFP expression intensity of CGR8-NS cells 
transfected with MC-GFP, pCMV-GFP and pVAX-eGFP (results are expressed as Mean ± SEM of 3 
independent experiments).  
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4.7. Differentiation of NSC 
 The differentiation potential of CGR8-NS cells into neurons after transfection was 
assessed by resuspending cells in HMB and transfecting them with 2.0 x 1011 molecules of 
pVAX-eGFP using 1800V, 20 ms and 1 pulse as microporation conditions. For neuronal 
differentiation non-microporated cells (Fig. 14A), microporated cells without DNA (Fig. 14B) 
and transfected cells (Fig. 14C) were submitted to the protocol described by  Spiliotopoulos 
et al [31] and the result was determined by labeling of the neuronal marker Tuj1 (Fig.14; 
green labeling, white arrows). Both microporation (without DNA) and transfection with pVAX-
eGFP did not seem to affect the CGR8-NSCs ability to differentiate into neurons; however, 
not many cells underwent differentiation, as it is shown by the low intensity of Tuj1 labeling. 
The difficulty in controlling the cell number after transfection, an essential factor in the 
neuralization protocol, might be the cause of this effect; therefore further experiments need 
to be performed to confirm the obtained results.  
 
 
A) 
C) 
B) 
Figure 14: CGR8-NSC neuronal 
differentiation after microporation and 
transfection.  
CGR8-NS cells were microporated and 
transfected with 2.0 x 10
11
 molecules of pVAX-
eGFP. 3 days after transfection cells were 
submitted to neuronal differentiation and the 
result was confirmed through Tuj1 labeling 
(green, white arrows). The nuclei were labeled 
with DAPI (blue). A) Non-microporated cells. B) 
Microporated cells without DNA. C) pVAX-eGFP 
transfected cells. Tuj1 and DAPI labeling was 
detected by fluorescence microscopy and 
images were obtained using an amplification of 
400x. 
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5. Discussion 
 In the past few years, NSCs have been the subject of intensive study to understand their 
biology and clinical application potential. Due to their proliferative capacity, relatively easy 
isolation and differentiation potential in vitro, NSCs have been considered an excellent 
resource for regeneration and gene therapies, therefore, their putative use for the treatment 
of neurological diseases, such as, neurodegenerative disorders and brain cancer, attract the 
interest of scientists all over the world. One of the major hurdles so far, has been the 
development of efficient gene delivery techniques that can be used for clinical applications. 
These methods, of viral and non-viral origin, often have some drawbacks either related to the 
type of used vector or the low transfection efficiencies obtained. For genetic manipulation, 
and future clinical application, it seems that the use of non-viral methods is preferable, yet, 
the low and transient transfection efficiencies usually obtained with these methods, 
cytotoxicity and maintenance of cell properties constitute the major setbacks for their future 
therapeutic application, therefore, to achieve the best results it is important to combine the 
best transfection technique with the best vector without neglecting the easy and safe 
handling that needs to be considered. However, it seems that the quest to find the perfect 
combination of method and vector is still in the beginning and the opinions about this matter 
vary worldwide.  
 In this study, in order to efficiently test the effect of different vectors in transfection of 
CGR8-NS cells, microporation conditions were optimized for the usage of two different 
electroporation buffers.  Microporation is an efficient method that allows the obtainment of 
high transfection levels and cell viability and has proven to be efficient in transfection of 
several cell types [65-67]. However, being a recent developed technique to acquire the best 
results it is necessary to optimize the conditions in which the transfection of NSC will be 
performed. Transfection by microporation is usually impaired by voltage, pulse duration and 
number of pulses; nonetheless, the used electroporation buffer is also an important factor to 
take into account and, as recent reports showed, using cheaper buffers of known 
composition might result in good transfection efficiencies and improved survival [81-82]. For 
optimization of microporation conditions, CGR8-NS cells were resuspended in RB, a 
commercial electroporation buffer of unknown composition, provided by the equipment 
manufacturer, and HMB, a homemade electroporation buffer that was previously used in 
transfection of HEK293T cells and mesenchymal stem cells and proven to give rise to high 
transfection efficiencies and better cell viability values [65, 79].  
 When analyzing the obtained results it was possible to conclude that for transfection of 
CGR8-NS cells the preferred microporation condition, when using RB is 1500V, 20 ms and 1 
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pulse. With the first and second optimization assays, where voltage and pulse duration were 
tested, the highest transfection efficiency (≈60%) and cell viability and recovery (around 85-
90%) values, and consequently, better yields of transfection (from 52 to 72%) were obtained 
upon transfection with 1500 V, 20 ms and 1 pulse. CGR8-NS cells proved to be resistant to 
high voltages, however, their survival, and as a consequence, the percentage of GFP+ cells, 
was highly affected with the increase of pulse duration from 20 to 30 ms.  In the third 
optimization assay using RB, the DNA amount was tested and optimized for transfection of 
CGR8-NS cells. Although the amount of DNA didn’t seem to affect the number of GFP 
expressing cells (≈50%), higher cell recovery (≈86%) and yield of transfection (≈40%) was 
obtained when using 0.8 µg of pDNA. This fact is in agreement with the manufacturer 
instruction, and with recent reports which suggest the use of low amounts of DNA in 
microporation assays is more beneficial in terms of cell viability and consequently recovery 
and yield of transfection [65, 79].  
 When using HMB, to obtain high transfection efficiency values it was necessary to 
increase the voltage until 1800 V. In this condition it was able to achieve high numbers of 
GFP expressing cells, which, depending on the vector, varied from 58 to 75%, with a relative 
decrease of cell viability and recovery values (from 77 to 83% and 67 to 86%, depending on 
the vector), being the lower values the ones correspondent to the same vector used in 
optimization with RB.  In fact, previous studies stated that there is a direct correlation with the 
increase of the voltage and transfection efficiency and cell death [83], therefore, as it can be 
seen from the obtained results, with the appropriate microporation condition it is possible to 
achieve high percentages of GFP expressing cells, however, the voltage increase might 
cause a slight decrease of the survival of the cells when using HMB.  
 In this study, the main objective was to test the effect of different vectors with distinct 
content of CpG dinucleotides on CGR8-NSCs transfection. When using a non-viral technique 
to transfect any type of cell, apart from the method, it is also important to wisely choose the 
ideal vector. These vectors are usually plasmids, that carry the gene of interest within an 
expression cassette that upon transfection is transcribed and translated [59].  The presence 
of unmethylated CpG dinucleotides in plasmid DNA can trigger immune responses thus 
increasing the risk of cytotxicity and impairing transgene expression.  Once inside the cell, 
CpG motifs are recognized by TLR9. These receptors become activated and recruit the 
protein MyD88 that activates a signal cascade that leads to degradation of foreign DNA and 
the activation of innate and adaptive immune responses [84]. In NSCs the presence of TLR9 
was not yet confirmed, however, the expression of many other Toll-Like receptors by aNSCs 
[85] suggest that their expression might be induced by the presence of bacterial CpG 
dinucleotides. The use of plasmids with reduced CpG content has shown to improve the 
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degree and persistence of gene expression and more recently, the use of CpGfree plasmids 
has demonstrated that upon in vivo transfection there is no activation of inflammatory 
responses and gene expression is sustained for more than 56 day [73]. When comparing the 
transfection efficiency of CGR8-NS cells transfected with CpGfree plasmids and pVAX-
eGFP, a plasmid that has been shown to have improved resistance to the host nucleases 
hence allowing efficient transfection of CHO cells [1], it was evident that the pCpGfree was 
fast diluted and showed lower levels of gene expression. The commercial plasmid used for 
this testing was completely devoid of CpG motifs, however, for that purpose, all its 
sequences were either modified or newly synthesized, therefore, the problem with the levels 
and duration of transfection might be a consequence of this fact and, the modification of the 
promoter, which comprises a CMV enhancer, the EFI-a core promoter and a 5’-UTR 
containing a synthetic intron, and the polyA sequence, the late SV40 polyadenylation 
sequence, might be the factors responsible for this plasmid’s weak performance.  
Further experiments were performed with other vectors, such as the minicircle (2.2 Kb) 
and its correspondent plasmid, pCMV-GFP (3.5 Kb) and the results were compared with 
transfection with pVAX-eGFP (3.7 Kb). Minicircles are small vectors of plasmid origin that are 
completely devoid of bacterial sequences and therefore, have a lower content of CpG 
dinucleotides. These vectors represent a new alternative oh highly efficient and safe non-
viral gene transfer and have been shown to induce a 10- to 10,000-fold improvement in the 
level and duration of gene expression [76-78]. In agreement with these data, the level of 
expression obtained with Minicircles in CGR8-NS cells was significantly higher, and more 
persistent when compared to its correspondent plasmid, pCMV-GFP, and also when 
compared with the other plasmid, the pVAX-eGFP. Significant differences were obtained 
among the three used vectors being the Minicircle the one that overall showed the better 
results, exhibiting an increase in GFP expression in the first 3 days reaching the maximum of 
75% of GFP+ cells with the maintenance of cell viability at around 90%. In contrast, although 
pCMV-GFP transfected cells showed the same decline in the percentage of GFP+ cells, the 
values didn’t go beyond 58% and cell viability was maintained at around 80%. Upon 
transfection with pVAX-eGFP the level of GFP expression reached its maximum (≈38%) on 
day 1, and cell viability values were maintained at around 70%.   In comparison with the 
other plasmids which have around 7% of CpG dinucleotides in their constitution, the MC-
GFP harbors only 6% of CpG dinucleotides and is smaller in size. It has been suggested 
that, upon transfection there is a size-dependent correlation with the mobility of the vector, 
indicating that, due to the presence of organelles that impose a high molecular crowding in 
the cytoplasm, the mobility of larger plasmids decrease making them more susceptible to 
degradation within the cell by the action of host nucleases [68-69]. Therefore, not only the 
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lack of bacterial backbone and low CpG content, but also the size of the minicircles might 
contribute to their improved performance, and in fact, recent studies demonstrated that 
reduced sized vectors contribute to enhanced gene expression level [Results from Ribeiro et 
al, under submission].  
In terms of proliferation kinetics it seemed that the presence of minicircles and pCMV-
GFP had no effect on cell division, while the presence of pVAX-eGFP seemed to slightly 
delay the proliferation on day 4 after transfection. These data could be also conf irmed by the 
analysis of the morphology and cell numbers. Unlike minicircle and pCMV-GFP transfected 
cells, the ones transfected with pVAX-eGFP were present in small numbers and had a 
rounder morphology, and, when analyzing the overall cell viability, pVAX-eGFP transfected 
cells always showed the lower values, hinting that with the transfection, their survival and 
metabolism was affected. In previously described reports some authors have observed 
slowdown of cell growth and lower viabilities due to GFP expression and increased apoptosis 
due to the presence of pDNA [86-87], however, the obtained results indicate that NSCs might 
be resistant to transgene expression still, at some point they can be affected by the presence 
of plasmid DNA. In this case, since the slowdown was only detected in low rates with pVAX-
eGFP, it can be concluded that NSCs biological response to pDNA transfection depends on 
the plasmid itself. As a matter of fact, recent studies demonstrated that upon transfection of 
the same gene with two different groups of plasmids significant differences were found in 
terms of cell apoptosis and consequently, cell viability [50].  Moreover, in this study and 
similarly to previous reports [50, 88], transfection didn’t seem to affect NSCs ability to 
differentiate, and even after microporation with pVAX-eGFP, CGR8-NS cells specified into 
neurons. 
In addition, uptake of vector copies by the nucleus was detected for CGR8-NS cells. 
Nuclear uptake of DNA vectors is usually affected by extra- and intracellular barriers; 
therefore, the obtained level of expression is never a translation of the entire supplied vector 
DNA. Recent studies showed that, although the nucleus can take large amounts of vector 
copies, only at low plasmid copy numbers gene expression can be correlated to the number 
of vector copies, and, there is a certain dose of vector after which the additional number of 
vector copies will not influence the level of transgene expression [89]. Recent reports 
determined that, depending on the used method and vector, only 1 to 10% of the delivered 
plasmids can be detected in the nuclei, and for example, in B16F10 mouse carcinoma cells 
and A549 human lung carcinoma cells, transfected with lipofectamine lipoplexes or 
polyethylenimine polyplexes, only 1 to 5% of the input DNA was detected in the nuclei [89-
90]. With the quantification of intranuclear vectors it was possible to determine that the dose 
after which the transgene expression level stabilizes is around 0.8 µg of vector DNA. 
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Minicircles were the vectors that showed higher expression levels, even though in some 
cases fewer copies of minicircles were detected inside the nucleus. Moreover, long-term 
quantification showed that the minicircles are less degraded, exhibiting higher number of 
copies and GFP expression than pCMV-GFP and pVAX-eGFP transfected cells. These 
results demonstrate that the increase of just 1% of the CpG content in pCMV-GFP and 
pVAX-eGFP is enough to induce a faster and stronger inflammatory response by the cells 
after transfection thus leading to higher plasmid degradation and episomal transgene 
silencing.    
The comparison of transfection efficiencies and number of GFP expressing cells show a 
big difference of values among the three tested vectors. The highest values were clearly 
obtained upon transfection with minicircles, however, even though pCMV-GFP and pVAX-
eGFP have similar CpG content, there was a significant divergence in the results. The major 
differences between pVAX-eGFP and pCMV-GFP are the polyadenylation signal and the 
GFP gene. While MC-GFP and pCMV-GFP contain the SV40 polyA signal, pVAX-eGFP 
contains the BGH polyadenylation signal. Azzoni et al demonstrated that different polyA 
signals can give rise to differences in gene expression and that the efficiency of a vector 
depends not only on its ability to overcome physical and metabolic barriers but also on the 
effectiveness of regulatory sequences, such as, promoter and polyA sequence which are 
directly correlated with the mRNA frequency and half-life [1]. Recent studies show that 
transfection of hMSC with -SV40 vectors allows higher transfection efficiencies in 
comparison to –BGH vectors, while on hNSCs, better levels of GFP expressing cells are 
obtained with vectors with BGH [Results from Ribeiro et al, under submission]. Our results 
seem to contradict these data and suggest that –SV40 based vectors are more efficiently 
translated in NSCs than –BGH plasmids, showing higher levels of expression, however, in 
the experiments accomplished herein, besides polyadenylation signals the two plasmids 
encode different GFP genes being currently impossible to conclude about the main factor 
responsible for the observed differences in GFP expression. To further confirm or refute 
these results, additional studies of mRNA quantification need to be performed. Moreover 
these results might also be a result of the level of purification of each plasmid, hinting that 
pVAX-eGFP is more contaminated with bacterial DNA than pCMV-GFP and Minicircle-GFP.  
 Until recently, most of the gene delivery experiments to NSCs relied on the use of 
viral methods to efficiently transfect these cells, however, the problems often associated with 
these vectors are slowly shifting the researcher’s attention to non-viral methodologies. Non-
viral transfection of these cells has shown to be difficult and not very efficient. Dhara et al 
transfected NPs by  nucleofection and obtained 37% of efficiency [91] while Sapet et al, 
using magnetofection with NeuroMag only achieved 15% of transfection efficiency [88]. 
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Tinsley et al managed to transfect around 11, 16 and 20% of cells using FuGene6, 
ExGen500 and lipofectamine, respectively [92-93]. This study has demonstrated that 
combining an efficient non-viral method of transfection, such as microporation, with the most 
appropriate vector, a better transfection efficiency of NSCs is achieved. Vectors of low CpG 
content and smaller in size are more efficiently maintained inside the cell. This study shows 
that the use of Minicircles allows the obtainment of high transfection efficiencies, allowing the 
transfection of nearly 75% of the cells, without compromising cell survival and morphology, 
and, independently of the used transfection method, these vectors represent a very 
promising alternative for efficient gene delivery to Neural Stem Cells and a hope to the 
development of therapeutic applications for the treatment of neurodegenerative diseases or 
even brain cancer.   
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6. Conclusions and Future work 
 In this study gene delivery to NSCs was accomplished by microporation and the 
transfection efficiency was analyzed, under optimized conditions, for different types of 
vectors, more specifically, minicircles and plasmids with different CpG content. Up to date, 
there are no published data of microporation assays in NSCs and transfection of these cells 
with minicircles, therefore this study offers the first insights in the use of both technologies in 
non-viral transfection of NSCs.  This study shows that non-viral transfection of NSCs by 
microporation constitutes an efficient method for gene delivery allowing the maintenance of 
the various cell traits and the obtainment of high expression levels. In conclusion this work 
demonstrates that the efficiency of non-viral gene delivery into NSCs can be increased by 
the use of small sized plasmids with low CpG content. In comparison with the other vectors, 
Minicircles showed improved transfection efficiency without compromising cell survival and 
morphology. Through the quantification of vector copies inside the nucleus it could be 
determined that the ideal dose of vector DNA to transfect NSCs is around 0.8 µg and it could 
be demonstrated that minicircles can be maintained inside the nucleus for longer periods of 
times and yield higher expression levels. Until recently one of the major problems related to 
minicircle technology was their production procedure, however, cheap and easy methods are 
being developed for large-scale production [74-75]. Altogether these results suggest that 
minicircles offer a new model of efficient and safe non-viral gene delivery to NSCs that can 
represent a desirable alternative for the development of therapies and clinical applications for 
the treatment of neurodegenerative diseases and brain cancer where a transient expression 
of the transgene might be necessary.   
 In terms of future work, to confirm if there is in reality an inflammatory response against 
CpG motifs it would be interesting to evaluate the expression of TLR9 of in vitro cultured 
NSCs after transfection with vectors of different CpG content. In order to evaluate the 
stability and frequency of transgene mRNA, it would also be interesting to quantify the 
number of mRNA copies after transfection with minicircles, pCMV-GFP and pVAX-eGFP and 
it would be beneficial to verify the efficiency of minicircles in gene delivery to NSCs using 
other transfection methods, such as Lipofection and Magnetofection. Additionaly, in vivo 
studies should be performed to evaluate the intracellular trafficking of minicircles.  
 Since this method is easy to handle and feasible, it would be interesting to clone 
minicircles with a gene of interest, such as BDNF or Shh, to direct gene induced neuronal 
differentiation [19-20], or others such as GDNF, VEGF and NGF or cytokines for in vivo 
testing of their effect in various neurodegenerative diseases, such as, Parkinson’s disease, 
Alzheimer’s disease or Spinal cord injury, and brain cancer. 
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
Supplementary Figure 1: Restriction maps of the commercial vectors pCMV-GFP and MC07.CMV-GFP (MC-
GFP) and the pVAX-eGFP construction.  
A) Restriction map of pCMV-GFP, consisting of: CMV enhancer/promoter; GFP sequence (Plasmid Factory); SV40 
polyA signal; bacterial origin of replication (ori) and a Kanamycin resistance gene. B) Restriction map of 
MC07.CMV-GFP, consisting of: CMV promoter, GFP sequence (Plasmid Factory); SV40 polyaA signal and res/tag 
sequence (site-specific recombination sequence). C) Restriction map of the construction pVAX-eGFP consisting of: 
CMV promoter, Bovine growth hormone polyA signal (BGH pA); Kanamycin resistance gene; bacterial origin of 
replication (pUC) and eGFP sequence that was inserted as previously described by Azzoni et al. 
 
  
Supplementary Figure 2: Schematic representation of Minicircle induction procedure developed by 
System Biosciences. 
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Supplementary Table 1: Percentage of CpG motifs in each DNA vector 
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Size (bp) 
No. CpG motifs 
(bp) 
% CpG 
motifs 
MC-GFP 2257 129 5.7 
pCMV-GFP 3487 230 6.6 
pVAX-eGFP 3697 248 6.7 
A B 
Supplementary Figure 3: Comparison of transfection efficiencies of CGR8-NSCs resuspended in RB 
and microporated using 1500V/20ms/1p and 1500V/30ms/1p as microporation parameters.  
CGR8-NSCs were transfected with 1 µg of pVAX-eGFP and analyzed 24h after microporation; A) Percentage 
of GFP expressing cells was assessed by flow cytometry and B) Yield of Transfection was assessed by trypan 
blue exclusion method and flow cytometry. NM cells were used as controls (Control viability ≈92%, not shown) 
and the results are expressed as mean ± SEM of two independent experiments. 
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Supplementary Figure 4: Phase contrast (left) and fluorescence (right) microscopic view of transfected 
CGR8-NS cells.   
CGR8-NSCs were ressuspended in RB and transfected with 2.0 x 10
11
 molecules of DNA vector. Images (100x) 
were obtained after 24h for CGR8-NS cells transfected with A,B) MC-GFP, C,D) pCMV-GFP and E,F) pVAX-
eGFP.   
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